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Cancer	 remains	 one	 of	 the	 leading	 causes	 of	 death	 worldwide	 due	 to	 late	 diagnosis	 and	
ineffective	treatment	options.	To	address	this	problem	requires	the	elucidation	of	the	molecular	




of	 the	 T-box	 factor	 TBX3,	 has	 been	 reported	 to	 function	 in	 promoting	 immortalization,	
migration,	 invasion	 and	 tumour	 formation	 in	 a	 number	 of	 epithelial-derived	 malignancies.	
Furthermore,	our	laboratory	recently	reported	that	TBX3	is	also	overexpressed	in	a	wide	range	
of	 sarcoma	 subtypes	 including	 rhabdomyosarcomas.	 This	 suggests	 that	 TBX3	 may	 also	
contribute	to	the	development	and/or	progression	of	sarcomas	and	potentially	may	serve	as	a	
biomarker	 for	 their	 diagnosis	 and	 targeted	 therapy.	 This	 is	 exciting	 because	 sarcomas	 are	
diverse	and	heterogeneous	cancers	with	varying	clinical	behaviours,	high	rates	of	metastasis	and	
recurrence	and	are	notoriously	resistant	to	current	chemotherapies.	However,	whether	TBX3	is	
a	 molecular	 driver	 of	 these	 mesenchymal-derived	 cancers	 remains	 to	 be	 determined.	 This	
project	 therefore	 aimed	 to	 elucidate	 the	 role	 of	 TBX3	 overexpression	 in	 embryonal	
rhabdomyosarcomas	 (ERMS)	 which	 is	 the	 most	 common	 soft	 tissue	 sarcoma	 in	 children	 and	
adolescents.	To	this	end,	ERMS	cell	culture	models	were	established	 in	which	TBX3	was	either	





data	 from	 initial	 experiments	 reveal	 that	 Hsc70	 interacts	 with	 TBX3,	 to	 possibly	 increase	 its	
protein	 stability,	 and	 that	oncogenic	 c-Myc	and	AKT1	positively	 regulate	TBX3	 levels	 in	ERMS.	
This,	albeit	preliminary	data,	 suggest	 that	Hsc70,	 c-Myc	and	AKT1	are	 responsible,	 in	part,	 for	
the	 overexpression	 of	 TBX3	 in	 ERMS.	 Together	 findings	 from	 this	 study	 implicate	 TBX3	 as	 an	








The	 wonder	 of	 life	 is	 the	 process	 of	 a	 single	 fertilized	 egg	 developing	 into	 a	 complex,	
multicellular,	fully	functional	organism.	This	intricate	dance	requires	precise	and	controlled	
co-ordination	of	gene	expression	by	transcription	factors	and	signaling	pathways.	Disruption	
in	 this	 delicate	 choreography	 can	 have	 catastrophic	 consequences	 regarding	 the	
development	 and	 homeostasis	 of	 an	 organism.	 For	 example,	 the	 T-box	 family	 of	
transcription	factors	play	an	 important	role	 in	embryonic	development	and	the	patterning	
of	 many	 tissues,	 and	 mutations	 in	 several	 members	 of	 this	 family	 result	 in	 congenital	
disorders.	 Furthermore,	 their	 deregulated	 expression	 has	 also	 been	 implicated	 in	 many	
carcinomas	 and	 more	 recently	 in	 sarcomas,	 including	 some	 of	 the	 most	 aggressive	 and	
treatment	resistant	malignancies.	Sarcomas	are	aggressive,	malignant	tumours	that	develop	
in	 bone	 and	 soft	 tissues	 with	 a	 relatively	 poor	 prognosis.	 They	 are	 a	 complex	 group	 of	
cancers	derived	from	the	mesenchyme	and	there	are	more	than	75	sarcoma	subtypes	that	
exhibit	 different	 biologies	 and	 clinical	 behaviours.	 Sarcomas	 are	 difficult	 to	 treat	 and	 are	
largely	 resistant	 to	 current	 chemotherapeutics.	 This	 is	 in	 part,	 because	 there	 is	 a	 lack	 of	
adequate	 diagnostic	 markers	 for	 early	 and	 accurate	 classification	 of	 subtypes,	 30%	 of	
sarcomas	metastasize	and	20%	recur.	Therefore	elucidating	the	status,	role	and	regulation	
of	 key	molecular	 drivers	 of	 the	 various	 sarcoma	 subtypes	will	 greatly	 benefit	 the	 field	 in	
terms	 of	 diagnostics	 and	 more	 effective	 combination-targeted	 treatment	 options.	 Of	





Transcription	 factors	 are	 master	 regulators	 of	 gene	 expression	 and	 are	 key	 players	 in	
embryogenesis	where	they	regulate,	amongst	other	processes,	cell	proliferation,	apoptosis,	
cell	migration	and	 invasion	 into	 surrounding	 tissues.	Considering	 that	 these	processes	are	
	 17	
also	 key	 features	 of	 oncogenesis,	 it	 is	 not	 surprising	 that	 the	 deregulated	 expression	 and	
activity	 of	 transcription	 factors	 are	 a	 feature	 of	 cancer	 initiation	 and	 progression	 (Lewis,	
2000).	An	example	 is	the	T-box	transcription	factor	family	which	derive	their	name	from	a	






that	 was	 described	 in	 1927	 by	 the	 Russian	 surgeon	 and	 scientist	 Nadine	 Dobrovoskaia-
Zavadskaia.	 She	 observed	 that	 mice	 with	 homozygous	 loss	 of	 Brachyury	 died	 in	 utero	
whereas	heterozygous	mice	failed	to	complete	full	tail	development	and	consequently	had	
short	 tails	 (Dobrovolskaia-Zadvadskaia,	 1927).	 MacMurry	 and	 Shin	 (1988)	 showed	 that	
deletions	of	different	allelic	forms	of	Brachyury	result	in	a	gradient	of	protein	levels	and	that	
this	 impacted	 on	 the	 severity	 of	 the	 short	 tail	 phenotype.	 This	 was	 the	 first	 study	 to	
illustrate	 that	 T-box	 proteins	 exhibit	 dosage	 sensitivity.	 The	 mouse	 Brachyury	 was	 later	
cloned	 (Hermman	 et	 al.,	 1990)	 and	 subsequent	 homologues	 were	 identified	 in	 several	
vertebrates	and	invertebrates	confirming	the	existence	of	the	ancient	T-box	family	(Figure	
1.1)	(Klava	&	Green,	1997;	Smith,	1999).	Phylogenetic	and	genomic	analyses	have	traced	the	
origins	 of	 this	 gene	 family	 back	 to	 a	 common	 ancestor	 that,	 through	 gene	 duplication	
events,	 further	diverged	 along	 individual	 lineages.	 This	 has	 allowed	different	 T-box	 family	
members	to	acquire	unique	functions	and	spatial	and	temporal	expression	patterns,	while	
retaining	 a	 conserved	 T-box	 domain	 (Agulnik	 et	 al.,	 1996;	Minguillon	 &	 Logan,	 2003).	 In	
mammals	 the	T-box	 family	 consists	of	18	members	and	 they	have	been	grouped	 into	 the	




Figure	 1.1:	 Evolutionary	 history	 of	 the	 T-box	 gene	 family.	 (A)	 Conservation	 of	 the	 T-box	 domain	 across	 a	
number	of	T-box	factors	 in	different	species.	H.s.,	Homo	sapiens;	X.l.,	Xenopus	 laevis;	D.r.,	Danio	rerio;	D.m.,	
Drosophila	 melanogaster;	 C.b.,	 Caenorhabditis	 briggsae;	 C.e.,	 Caenorhabditis	 elegans	 (taken	 from	
Papaioannou	et	al.,	2014).	(B)	Phylogenetic	analysis	of	the	T-box	family	in	vertebrates.	These	T-box	genes	are	
present	 in	 human	 and	 mouse	 with	 the	 exception	 of	 the	 zebrafish	 genes	 Drtbx16	 and	 Drtbx6	 (taken	 from	






development	 where	 they	 function	 in	 early	 embryogenesis,	 germ	 layer	 specification,	 limb	
patterning	 and	 organogenesis	 (reviewed	 in	 Papaioannou,	 2014).	 For	 example,	 TBX4	 and	
Eomesodermin	 contribute	 to	 trophoectoderm	 and	 allantois	 formation	 (Russ	 et	 al.,	 2000),	
TBX6	specifies	patterning	of	the	somites,	TBX2,	TBX3,	TBX5	and	TBX20	contribute	to	heart	
development,	 and	 TBX3,	 TBX4	 and	 TBX5	 are	 involved	 in	 limb	 formation	 (Naiche	 &	
Papaioannou,	 2003;	Naiche	et	 al.,	 2005).	 Their	 essential	 roles	 in	 development	 are	 further	
observed	in	the	congenital	disorders	that	arise	from	mutations	in	T-box	genes	as	described	
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in	 Table	 1.1	 (reviewed	 in	 Packham	 &	 Brook	 2003	 and	 Papaioannou,	 2014).	 The	 rare	
autosomal	dominant	disorder,	ulnar	mammary	syndrome	(UMS)	results	 from	mutations	 in	
the	 TBX3	 gene	 and	 will	 be	 discussed	 later	 under	 section	 1.4.2	 dealing	 with	 TBX3	 in	
development.		
	
The	T-box	domain	present	 in	 all	 T-box	 factors	 is	 approximately	 200	amino	acids	 long	 and	
does	 not	 have	 any	 sequence	 similarities	 to	 any	 known	 transcription	 factor	 DNA-binding	
domain	(Kispert	&	Herrmann,	1993).	Early	in	vitro	studies	of	Brachyury	found	that	the	T-box	
recognizes	 and	binds	 the	 “TCACACCT”	DNA	 sequence,	 called	 the	 T	 element,	 found	within	
the	nearly	palindromic	sequence	 [TTT(G/C)ACACCTAGGTGTGAAATT],	as	either	a	monomer	




activators	 (Ataliotis	et	al.,	 2005;	Zaragoza	et	al.,	 2004;	Gonzalez	et	al.,	 2013;	Maira	et	al.,	
2003;	Lingbeek	et	al.,	2002;	Stennard	et	al.,	2005;	Casey	et	al.,	1998),	others	such	as	TBX2,	
TBX3,	TBX15,	TBX18	and	TBX22	 function	predominantly	as	 repressors	 (Prince	et	al.,	 2004;	
Jacobs	et	al.,	2000;	Andreou	et	al.,	2007;	Carlson	et	al.,	2001;	Farin	et	al.,	2013).	In	addition	
there	 is	 evidence	 that	 Brachyury,	 TBX2,	 TBX3,	 TBX5,	 TBX20	 and	 Mga	 can	 act	 as	 both	
transcriptional	activators	and	repressors	(Carreira	et	al.,	1998;	Casey	et	al.,	1998;	Sakabe	et	
al.,	 2012;	 Prince	 et	 al.,	 2004;	 Wilmer	 et	 al.,	 2016;	 Lu	 et	 al.,	 2011;	 Carlson	 et	 al.,	 2001;	
Takeuchi	 et	 al.,	 1999;	 Zaragoza	 et	 al.,	 2004;	 Stennard	 et	 al.,	 2005;	 Singh	 et	 al.,	 2005;	
Kawamura	et	al.,	2008;	Hurlin	et	al.,	1999).	This	begs	the	question	as	to	what	switches	the	
activating	 versus	 repressing	 activity	 of	 these	 T-box	 factors.	 Furthermore,	 while	 all	 T-box	
factors	bind	and	 regulate	 the	same	consensus	T-element	 in	vitro,	 in	vivo	evidence	 reveals	
that	T-box	 factors	regulate	different	 target	genes,	are	 functionally	distinct	and	are	able	to	
bind	 highly	 variable	 and	 degenerate	 sites	 (Lingbeek	 et	 al.,	 2002;	 Boogerd	 et	 al.,	 2012).	
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TBX22	 Cleft	palate	 X-linked	 cleft	 palate	 (speech,	 feeding,	







co-factor	 binding	 sites	 (Lu	 et	 al.,	 2011;	 Papaioannou,	 2014).	 Indeed,	 several	 of	 lines	 of	







interaction	 with	 Ripply1	 in	 zebrafish	 embryos.	 Furthermore,	 the	 phenotype	 arising	 from	
aberrant	Ripply1	expression	is	similar	to	that	of	a	homozygous	Ntl	mutant	(Kawamura	et	al.,	
2008).	 In	 pituitary	 gland	 cells	 TBX19/Tpit	 is	 only	 able	 to	 activate	 pro-opiomelanocortin	
(POMC)	 gene	 expression	 by	 co-operation	 with	 Pitx	 binding	 to	 a	 contiguous	 site	 within	 a	
regulatory	region	of	the	promoter	(Lamolet	et	al.,	2001).	Indeed,	mutations	in	either	Tpit	or	
Pitx’s	 binding	 sites	 result	 in	 a	 loss	 of	 POMC	 transcription	 (Lamolet	 et	 al.,	 2001).	 During	
zebrafish	 heart	 development	 Sox4	 plays	 a	 critical	 role	 in	 mediating	 the	 transcriptional	
regulation	of	Connexin43	(Cx40)	expression	by	TBX3	(Boogerd	et	al.,	2011).	Moreover,	Nkx2-
5	 interacts	with	 Tbx2,	 Tbx3,	 Tbx5	 and	 Tbx20	 to	 influence	 their	 regulation	of	 their	 cardiac	
target	 genes	 during	mouse	 heart	 development	 (Bakker	 et	 al.,	 2008;	 Habets	 et	 al.,	 2002;	
Hoogaars	 et	 al.,	 2008;	 Hoogaars	 et	 al.,	 2004a;	 Stennard	 et	 al.,	 2003;	 Hiroi	 et	 al.,	 2001).	
Furthermore	 in	 rat	 brain	 development	 the	 protein	 partner	 complex	
Tbr1/Calcium/calmodulin-dependent	 serine	 protein	 kinase	 (CASK)	 regulates	 a	 number	 of	
target	 genes	 containing	 T-elements,	 for	 example	 Reelin	 (Hsueh	 et	 al.,	 2000;	Wang	 et	 al.,	
2004).	 In	 addition,	 TBX5	 requires	 direct	 association	 with	 co-activator	 Tafazin	 (TAZ),	 and	
histone	 acetyltransferases	 p300	 and	 PCAF,	 to	 stimulate	 TBX5	 dependent	 promoters	 in	
cardiac	and	limb	development	(Murakami	et	al.,	2005).	Lastly,	both	the	Smad	and	Groucho	
proteins	 interact	 and	 regulate	 the	 transcriptional	 activity	 of	 a	 number	 of	 T-box	 factors	
(Singh	et	al.,	2009;	Messenger	et	al.,	2005;	Miller	&	Okkema	2011;	Kawamura	et	al.	2008;	
Farin	et	al.,	2013)	and	T-box	 factors	have	also	been	 reported	 to	associate	with	chromatin	





In	addition	to	 their	critical	 roles	 in	embryonic	development,	a	growing	 list	of	studies	have	
also	linked	inappropriate	T-box	factor	expression	to	oncogenesis	and	several	T-box	factors,	
including	Brachyury,	 Eomes,	 TBX1,	 TBX2,	 TBX3,	 TBX4,	 TBX5	and	T-bet	 (TBX21),	 have	been	
implicated	to	directly	promote	and/or	suppress	tumour	formation		(He	et	al.,	2002;	Yu	et	al.,	





al.,	 2014).	 On	 the	 other	 hand,	 TBX4	 has	 been	 linked	 to	 decreased	metastasis	 and	 better	
overall	survival	in	pancreatic	ductal	cell	adenocarcinoma	(Qi	et	al.,	2008;	Zong	et	al.,	2011)	
and	 in	 colon	 cancer	 TBX5	 has	 been	 reported	 to	 decrease	 substrate	 dependent	 and	








TBX3	 is	 located	 on	 chromosome	 12	 at	 position	 12q23-24.1,	 spans	 a	 distance	 of	 13.9	 kb,	
consists	 of	 7	 exons,	 produces	 a	 transcript	 of	 5.2	 kb	 and	 encodes	 a	 723	 amino	 acid	 long	
peptide	 (Bamshad	et	al.,	 1997;	Rowley	et	al.,	 2004).	Due	 to	alternative	 splicing	 four	TBX3	
mRNA	transcripts	have	been	identified	but	only	two,	TBX3	and	TBX3+2a,	encode	full	length	








vitro	 and	 to	 repress	 senescence	 in	 mouse	 embryonic	 fibroblasts	 (MEFs),	 TBX3+2a	 was	
unable	 to	 bind	 and	 instead	 accelerated	 senescence	 in	 MEFs.	 The	 authors	 therefore	
concluded	 that	 the	 TBX3	 and	 TBX3+2a	 isoforms	were	 functionally	 distinct	 and	 suggested	
that	the	extra	20	amino	acids	in	the	DNA	binding	domain	of	the	TBX3+2a	isoform	may	either	
disrupt	 its	 ability	 to	bind	 target	DNA	or	may	 result	 in	 it	 regulating	different	 target	 genes.	
Consistent	 with	 the	 latter	 possibility,	 Zhao	 et	 al.	 (2014)	 showed	 that	 whereas	
overexpression	of	both	isoforms	in	mouse	embryonic	stem	cells	 induced	differentiation	by	
repressing	 pluripotency	 factor	 Nanog,	 only	 TBX3+2a	 could	 directly	 bind	 the	 Nanog	
promoter.	 On	 the	 other	 hand,	 Hoogaars	 et	 al.	 (2008),	 using	 DNA	 binding	 and	 structural	
studies,	 found	 that	 both	 isoforms	 were	 able	 to	 bind	 a	 consensus	 T-element	 in	 the	
p21Cip1/Waf1/CDKN4a/SDII	(referred	to	as	p21)	and	cardiac	natriuretic	peptide	A	(Nppa)	promoters	
as	 well	 as	 interact	 with	 the	 homeobox	 factor	 Nkx2-5.	 The	 authors	 also	 found	 that	 the	
ectopic	 expression	 of	 either	 isoform	 inhibited	 heart	 chamber	 formation	 and	 repressed	
cardiac	chamber	markers	Nppa	and	Cx40.	In	addition,	the	Prince	laboratory	has	found	that	
both	TBX3	and	TBX3+2a	are	able	to	bind	the	p21	promoter	and	have	comparable	ability	to	
repress	 p21	 expression	 (unpublished	 data;	 Wilmer	 et	 al.,	 2016b).	 Together	 the	 above	
studies	 suggest	 that	 the	 TBX3	 and	 TBX3+2a	 isoforms	 may	 exhibit	 functional	 differences	
depending	on	cellular	context.		
	
TBX3	 functions	 predominantly	 as	 a	 transcriptional	 repressor	 and	 indeed	 it	 represses	
p14ARF/p19ARF	(referred	to	as	p14/p19),	p21,	Nppa,	E-cadherin,	and	phosphatase	and	tensin	
homolog	 (PTEN)	 (Burgucu	 et	 al.,	 2012;	 Brummelkamp	 et	 al.,	 2002;	 Lingbeek	 et	 al.,	 2002;	
Rodriguez	et	 al.,	 2008;	Hoogaars	et	 al.,	 2008).	 Through	deletion	 constructs	 and	 luciferase	
assays	 Carlson	 et	 al.	 (2001)	 mapped	 the	 functional	 domains	 of	 TBX3	 and	 described	 two	
repression	domains	 (R1	and	R2)	as	well	as	an	activation	domain	 (Figure	1.2).	 Importantly,	
TBX3	C-terminal	mutants	linked	to	the	UMS	phenotype,	in	which	the	repression	domain	R1	
is	 lost,	 results	 in	 increased	 protein	 decay	 and	 loss	 of	 function	 (Carlson	 et	 al.,	 2001).	 It	 is	
important	 to	 note	 that	 TBX3	 can	 activate	 Gata6	 (Lu	 et	 al.,	 2011)	 in	 the	 context	 of	 heart	
development	but	whether	this	involves	the	putative	activation	domain	identified	by	Carlson	
et	 al.	 (2001)	 is	 not	 known.	 Carlson	et	 al.	 (2001)	 also	mapped	 the	 location	of	 TBX3’s	DNA	
































and	 the	 conduction	 system	 (Davenport	 et	 al.,	 2003;	 Naiche	 et	 al.,	 2005).	 TBX3	 is	 also	
expressed	 in	a	number	of	human	organs	 including	the	 foetal	heart,	 liver,	spleen,	 lung	and	
kidney,	 and	 adult	 prostate,	 lung,	 placenta,	 ovary,	 testis,	 small	 intestine,	 adrenal	 gland,	
thyroid,	 breast,	 bladder,	 uterus,	 nervous	 system,	 mammary	 gland	 and	 salivary	 gland	
(Bamshad	et	 al.,	 1999;	 Carlson	et	 al.,	 2001;	 Davenport	et	 al.,	 2003;	 He	et	 al.,	 2002).	 The	
critical	 developmental	 role	of	 TBX3	 is	 demonstrated	 in	 the	embryonic	 lethality	 associated	
with	 a	 homozygous	 mutation	 in	 mice,	 due	 to	 malformation	 of	 the	 yolk	 sac	 and	 cardiac	
abnormalities,	 and	 in	 the	 human	 ulnar	 mammary	 syndrome	 (UMS)	 that	 results	 from	
heterozygous	mutations	 in	 the	 human	TBX3	 gene	 (Hermann	et	 al.,	 1990;	 Bamshad	et	 al.,	
1997;	Davenport	et	al.,	2003).	
	




and	 urogenital	 malformations	 and	 abnormalities	 (Bamshad	 et	 al.,	 1997;	 Bamshad	 et	 al.,	
1999;	Packham	&	Brook,	2003).	It	is	noteworthy	that	while	TBX3	is	expressed	in	a	number	of	
developing	tissues	not	all	of	 them	are	affected	 in	UMS	suggesting	that	different	cell	 types	
display	 differing	 sensitivities	 to	 the	 level	 of	 TBX3.	 Aberrant	 TBX3	 associated	 with	 UMS	
include	truncated	versions	of	the	protein,	such	as	loss	of	the	R1	repression	domain	which	is	
associated	 with	 decreased	 or	 no	 transcriptional	 repression	 activity	 (Carlson	 et	 al.,	 2001).	
Klopocki	et	 al.	 (2006)	 described	 a	 novel	 1.28	Mb	deletion	 encompassing	 TBX3	 in	 a	 single	
patient	 that	 resulted	 in	 a	 UMS-like	 phenotype	 accompanied	 by	 dysmorphic	 facies	 and	
mental	retardation.	 In	mice	homozygous	TBX3	mutants	die	 in	utero	and	display	mammary	
gland	aplasia	 and	malformations	of	 the	 limbs,	 similar	 to	 the	human	UMS	phenotype,	 and	






result	 in	UMS	 and	 from	mass	 spectrometry	 of	 TBX3/protein-partner	 immunoprecipitation	
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samples	the	authors	found	that	TBX3	interacts	with	RNA	binding	and	splicing	factors	in	vivo.	
Furthermore,	 whereas	 TBX3	was	 able	 to	 directly	 bind	 T-box	 binding	motifs	 in	 the	mRNA	
transcripts	 of	 Disks	 large	 homolog	 (3Dlg3)	 and	 Nuclear	 factor	 of	 kappa	 light	 polypeptide	
gene	 enhancer	 in	 B-cells	 1	 (Nfκb1)	 and	 regulated	 their	 splicing,	 UMS-associated	 TBX3	
mutations	disrupted	this	splicing	regulatory	function.	TBX3	was	also	reported	to	be	capable	
of	recruiting	other	RNA	binding	and	splicing	factors	to	RNA	containing	T-elements,	such	as	








Consistent	 with	 TBX3	 being	 expressed	 in	 the	 inner	 cell	 mass	 of	 the	 blastocyst	 and	 its	
involvement	in	cell	fate	determination,	 it	has	been	implicated	to	play	pivotal	roles	in	stem	
cell	renewal	and	differentiation	(Papaioannou,	2014).	Indeed,	TBX3	has	been	grouped	with	
the	 pluripotency	 transcription	 factors	 Klf4/5,	 Nanog	 and	 Oct3/4	 as	 a	 stem-ness	 factor	
(Russell	 et	 al.,	 2015;	Waghray	 et	 al.,	 2015;	Weidgang	 et	 al.,	 2016).	 Furthermore,	 studies	
have	 reported	 that	 TBX3	 contributes	 to	mouse	 embryonic	 stem	 cell	 (mESC)	 renewal	 and	
that	loss	of	its	expression	results	in	differentiation	(Inavona	et	al.,	2006;	Zhao	et	al.,	2014).	
In	mESCs	TBX3	forms	part	of	the	core	pluripotency	signaling	pathway;	 it	 is	downstream	of	
the	Wingless	 (Wnt)	 and	 phosphoinositide	 3-kinase/Protein	 kinase	 B	 (PI3K/ATK)	 pathways	
that	stimulate	 its	expression,	and	the	MAPK	pathway,	which	antagonizes	 its	expression	to	
maintain	balance	(Niwa	et	al.,	2009;	Russell	et	al.,	2015;	Waghray	et	al.,	2015;	Weidgang	et	
al.,	 2016).	 Zhao	 et	 al.	 (2014)	 reported	 that	 both	 TBX3	 and	 TBX3+2a	 isoforms	 are	
overexpressed	 in	mouse	pluripotent	 stem	cells	and	 Inavona	et	al.	 (2006)	 found	 that	TBX3	
expression	 is	 needed	 to	 block	 differentiation	 into	mesoderm,	 ectoderm	 and	 neural	 crest	
cells	 in	mESC	 and	 that	 its	 downregulation,	 due	 to	 retinoic	 acid	 (RA)	 signaling,	 resulted	 in	




(Han	 et	 al.,	 2010).	 Interestingly,	 micro-RNAs	 (miRs)	 have	 been	 implicated	 in	 regulating	




fate	 specifications	 through	 either	 (1)	 transcriptional	 regulation	 of	 differentiating	 gene	









Considering	 the	 commonalities	between	developmental	 and	oncogenic	processes	 it	 is	 not	
surprising	 that	 TBX3	 has	 been	 implicated	 in	 many	 cancers.	 For	 example,	 TBX3	 is	
overexpressed	in	melanoma,	breast,	pancreatic,	liver,	ovarian,	head	and	neck	squamous	cell	
cancer	and	several	sarcoma	subtypes	(Hoek	et	al.,	2004;	Fan	et	al.,	2004;	Yarosh	et	al.,	2008;	
Liu	 et	 al.,	 2011;	 Rodriguez	 et	 al.,	 2008;	 Douglas	 &	 Papaioannou,	 2013;	 Lomnytska,	 2006;	
Hansel	 et	 al.,	 2004;	 Renard	 et	 al.,	 2007,	 Humtsoe	 et	 al.,	 2011;	 Burgucu	 et	 al.,	 2012;	
Wansleben	et	al.,	2014;	Willmer	et	al.,	2016).	Importantly,	increased	levels	of	TBX3	has	been	

















that	 it	 was	 able	 to	 immortalize	 MEFs	 by	 inhibiting	 senescence	 (Carlson	 et	 al.,	 2001).	
Senescence	is	a	safeguard	programme	that	describes	irreversible	exit	from	the	cell	cycle	and	
occurs	 in	 two	 forms:	 replicative	 and	 premature	 (Kuilsman	 et	 al.,	 2010;	 Campsi,	 2013).	
Replicative	senescence	occurs	 in	all	somatic	cells	once	they	have	reached	the	end	of	their	
finite	 lifespan	and	 is	triggered	by	the	shortening	of	their	telomeres	(Kuilsman	et	al.,	2010;	
Campsi,	 2013).	 Premature	 senescence,	 also	 known	 as	 accelerated	 senescence,	 occurs	 in	
response	 to	 stressful	 stimuli	 such	 as	 DNA	 damage,	 oncogene	 overexpression	 and	
inflammation,	 forcing	 the	 cell	 to	withdraw	 from	active	 cell	 division	before	 it	 causes	more	




Yarosh	 et	 al.	 (2008)	 later	 revealed	 that	 this	 occurs	 in	 part	 by	 TBX3	 recruiting	 histone	
deactyelaces	(HDACs)	1,	2,	3	and	5	to	epigenetically	silence	the	p14/p19	promoter.	The	p19-
murine	double	minute	2	 (MDM2)-p53	pathway	plays	an	 important	 role	 in	protecting	 cells	
against	oncogenic	transformation.	For	example	in	response	to	cellular	stress,	p14/p19	acts	
to	stabilize	p53	by	sequestering	ubiquitin	ligase	MDM2	and	preventing	its	association	with	
p53	 (Sherr	 &	 Weber,	 2000;	 Sharpless	 &	 DePinho,	 1999).	 This	 allows	 p53	 to	 upregulate	
important	 cell	 cycle	 checkpoint	 initiators,	 pro-senescence	 and/or	 pro-apoptosis	 factors.	
Thus	 when	 p14/p19	 is	 repressed,	 MDM2	 is	 released	 and	 ubiquitinates	 p53	 leading	 to	
increased	 shuttling	 of	 p53	 out	 of	 the	 nucleus	 and	 its	 proteolytic	 degradation	 by	 the	
proteasome	 26S	 in	 the	 cytoplasm	 (Sherr	 &	 Weber,	 2000;	 Sharpless	 &	 DePinho,	 1999;	
Brummelkamp	 et	 al.,	 2002).	 Consequently	 the	 levels	 of	 p53	 target	 genes	 that	 promote	
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senescence	 such	 as	 p21	 are	 decreased.	 Kumar	 et	 al.	 (2014b)	 recently	 reported	 on	 an	
alternative	mechanism	by	which	TBX3	may	be	bypassing	senescence.	They	showed	that	the	
TBX3/Co-activator	 of	 AP1	 and	 Estrogen	 Receptor	 (CAPERα)	 complex	 directly	 repressed	







proliferation,	 translates	 into	 an	 increase	 in	 the	 risk	 of	 cancer	 progression	 as	 well	 as	 in	
resistance	 to	anti-cancer	drugs	 (Schmitt	et	al.,	 2007).	 Several	 studies	have	 suggested	 that	
TBX3	may	also	contribute	to	oncogenesis	by	promoting	the	evasion	of	apoptosis.	Carlson	et	




to	 the	 chemotherapeutic	 doxorubicin	 (Ito	 et	 al.,	 2005;	 Renard	 et	 al.,	 2007).	 In	 addition,	
Humtsoe	et	al.	 (2012)	observed	that	TBX3	expression	protected	head	and	neck	squamous	
cell	 carcinoma	 cells	 against	 anoikis,	 a	 specific	 form	 of	 cell	 death	 induced	 by	 anchorage-













TBX3	 represses	 p21	 through	 directly	 binding	 to	 a	 T-element	 in	 its	 promoter	 leading	 to	
increased	 proliferation	 in	 chondrosarcomas.	 High	 levels	 of	 TBX3	 also	 correlated	 with	
proliferation,	 invasion,	metastasis	and	tumour	size	 in	uterine	and	cervical	primary	 tumour	
samples	 (Lyng	 et	 al.,	 2006).	 Another	 mechanism	 by	 which	 TBX3	 stimulates	 proliferation	
appears	to	involve	its	ability	to	transcriptionally	inhibit	the	tumour	suppressor	PTEN	in	head	
and	neck	squamous	cell	carcinoma	(Burgucu	et	al.,	2012).	PTEN	acts	as	a	tumour	suppressor	
by	 negatively	 regulating	 the	 PI3K/AKT	 pathway	 and	 pro-oncogenic	 processes,	 such	 as	






Prince,	 2013).	 This	 phenomenon	 is	 known	 as	 the	 proliferation/migration	 dichotomy	 of	





Li	 et	 al.	 (2013)	 reported	 that	 transforming	 growth	 factor	 β1	 (TGF-β1)	 signaling	
transcriptionally	activated	TBX3	expression,	via	downstream	mediators	Smad	3/4	and	JunB	
binding	 to	 its	 promoter,	 and	 this	 reduced	 proliferation	 yet	 boosted	 migration	 of	 breast	
epithelial	 cells.	 Together	 the	above	 studies	 suggest	 that	 the	 role	of	 TBX3	 in	promoting	or	
inhibiting	 proliferation	 is	 cell	 context	 dependent	 which	 again	 may	 be	 dependent	 on	 the	
availability	of	co-factors.		
	




anchorage	 independent	 cell	 proliferation,	 tumour	 formation,	 migration,	 invasion,	
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metastasis,	 resistance	 to	 chemotherapeutics	 and	 recurrence	 (Figure	 1.3).	 Indeed,	our	and	
other	laboratories	have	shown	that	TBX3	plays	an	important	role	in	tumour	formation	and	
invasion	in	breast	cancer,	melanoma	and	chondrosarcoma	(Peres	et	al.	2010;	Renard	et	al.	
2007;	 Rodriguez	 et	 al.	 2008;	 Mowla	 et	 al.	 2010;	 Wilmer	 et	 al.,	 2016).	 For	 example,	
ectopically	overexpressing	TBX3	was	sufficient	 to	promote	tumour	 formation	and	 invasion	
of	 non-tumourigenic	 early	 stage	 radial	 growth	 phase	 melanoma	 cells	 in	 nude	 mice	 and	
promoted	 anchorage	 independent	 proliferation,	 tumour	 formation	 and	 migration	 in	
chondrosarcomas	(Peres	&	Prince;	2013;	Wilmer	et	al.,	2016).	Importantly,	when	TBX3	was	
knocked	 down	 in	 advanced	 melanoma	 cells	 using	 a	 shRNA	 approach	 the	 cells	 lost	 their	
ability	to	form	tumours	and	were	unable	to	migrate	and	invade	surrounding	tissues	(Peres	
et	al.,	2010).	Similarly,	knocking	down	TBX3	in	breast	cancer	and	chondrosarcomas	reversed	




allow	 for	 cell	migration	 (Rodriguez	et	al.,	 2008;	Peres	et	al.,	 2010).	Humstoe	et	al.	 (2012)	
also	 observed	 that	 head	 and	 neck	 squamous	 carcinoma	 cells	 undergoing	 an	 epithelial-to-
mesenchymal-like	 transition	 had	 high	 levels	 of	 TBX3	 but	 low	 levels	 of	 E-cadherin.	





processes,	 information	 about	 the	mechanisms	 involved	with	 its	 upregulation	 in	 cancer	 is	
only	 beginning	 to	 emerge.	 As	 previously	 mentioned,	 TGF-β1	 signaling	 upregulated	 TBX3	
expression	 in	 breast	 cancer	 cells	 which	 in	 turn	 promoted	 cell	 migration	 (Li	 et	 al.,	 2014).	
Mowla	 et	 al.	 (2011)	 similarly	 found	 that	 treating	 breast	 cancer	 cells	 with	 phorbol	 12-
myristate	 13-acetate	 (PMA)	 induced	 TBX3	 levels	 and	 caused	 increased	 cell	 migration.	
Moreover,	 in	 colon	 and	 liver	 cancer	 cells	 TBX3	 expression,	 induced	 by	 the	 constitutively	
active	 Wnt/β-catenin	 pathway,	 promoted	 cell	 survival,	 anchorage	 independent	 growth,	




Cancer	 stem	 cells	 (CSCs)	 rely	 on	 developmental	 signaling	 pathways	 and	 therefore	
recapitulate	the	development	process;	they	are	particularly	aggressive	as	they	promote	cell	
survival,	 self-renewal	 and	 expansion	 that	 sustains	 tumour	 growth,	 progression	 and	
recurrence	as	well	as	resistance	to	anti-cancer	therapies	(Clarke	et	al.,	2006;	Fillmore	et	al.,	
2010).	Fillmore	et	al.	 (2010)	reported	that	estrogen/FGF/FGFR/TBX3,	as	well	as	Wnt/TBX3,	
signaling	 expanded	 breast	 cancer	 stem	 cell	 populations,	 contributing	 to	 tumour-forming	





While	TBX3	 functions	predominantly	as	a	 tumour	promoter,	 there	 is	 also	evidence	 that	 it	
may	 act	 as	 a	 tumour	 suppressor.	 For	 example,	 TBX3	 is	 epigenetically	 silenced	 in	
glioblastoma,	bladder	 and	gastric	 cancer	 (Kandimalla	et	al.,	 2012;	 Etcheverry	et	al.,	 2010;	
Yamashita	 et	 al.,	 2006)	 and	 downregulated	 in	 uterine	 cervical	 cancer	 (Lyng	 et	 al.,	 2006).	
Microarray	 data	 and	 genomic	 analyses	 revealed	 that	 when	 TBX3	 is	 downregulated	 and	
silenced	via	methylation	in	uterine	cervical	cancer	and	glioblastoma	respectively,	its	lack	of	
expression	 is	 associated	 with	 increased	 invasion,	 metastasis,	 tumour	 size	 and	 poor	
prognosis	 (Figure	 1.3)	 (Yamashita	et	 al.,	 2006;	 Lyng	et	 al.,	 2006;	 Etcheverry	et	 al.,	 2010).	
Based	on	this	data	 it	was	suggested	that	 the	expression	profile	of	TBX3	may	be	used	as	a	
marker	 of	 metastasis	 and	 prognosis.	 Similarly,	 Kandimalla	 et	 al.	 (2012)	 found	 that	 TBX3	
methylation	 was	 associated	 with	 worse	 progression-free	 survival	 in	 bladder	 cancer.	
Importantly,	 recently	 TBX3	 was	 shown	 to	 act	 as	 a	 tumour	 suppressor	 in	 fibrosarcomas,	
acting	to	reduce	substrate	dependent	and	independent	cell	proliferation,	tumour	formation	
and	migration	(Wilmer	et	al.,	2016).	Together,	the	above	studies	suggest	that	whether	TBX3	










Figure	 1.3:	 The	 role	 of	 TBX3	 in	 cancer	 formation.	 TBX3	 has	 been	 shown	 to	 contribute	 to	 several	 cancer	
processes	 including	 the	 bypass	 of	 senescence	 (Brummelkamp	 et	 al.,	 2002),	 evasion	 of	 apoptosis,	 drug	
resistance	(Carlson	et	al.,	2002;	Zhang	et	al.,	2010;	Humtsoe	et	al.,	2012)	and	the	promotion	of	proliferation,	









































derived	 tissues.	 Approximately	 80-90%	 of	 sarcomas	 originate	 from	 soft	 tissue	 (muscles,	
joints,	 fat,	 nerves,	 deep	 skin	 tissues,	 and	 blood	 vessels)	 and	 the	 remaining	 10-20%	 from	
bone	 and	 cartilage	 (Koch	et	 al.,	 2002;	 Burmingham	et	 al.,	 2012).	 They	make	up	 1%	of	 all	
existing	 cancers	 in	 adults,	 10%	 in	 children	 and	 8%	 in	 adolescents	 (Mackall	 et	 al.,	 2002;	
Helman	 &	 Metzler,	 2003;	 Ducimetiere	 et	 al.,	 2011;	 Amankwah	 et	 al.,	 2013).	 In	 general,	








Traditionally	 sarcomas	 have	 been	 classified	 via	 histopathology	 using	 light	 microscopy	 by	
examining	 cell	 lineage	 morphology,	 differentiation,	 staining	 for	 cell-specific	 markers	 and	
identifying	resemblance	to	a	normal	tissue	type	(Osuna	&	De	Alava,	2009).	Thus	sarcomas	
were	 named	 after	 their	 tissues	 of	 origin,	 for	 example,	 fibrosarcomas	 from	 fibrous	 tissue,	
rhabdomyosarcoma	from	skeletal	muscle,	osteosarcoma	from	bone,	 leiomyosarcoma	from	
smooth	 muscle,	 chondrosarcoma	 from	 cartilage,	 liposarcoma	 from	 adipose	 tissue	 and	
angiosarcoma	from	blood	vessels	(Helman	&	Metzler,	2003).	There	are,	however,	challenges	
with	 using	 histopathology	 for	 classifying	 sarcomas	 as	 a	 large	 proportion	 are	 high-grade,	
poorly	 differentiated	 and	 pleomorphic	 (Doyle,	 2014).	 Indeed,	 until	 the	 early	 1990’s	 the	
misclassification	rate	of	sarcomas,	based	on	histopathological	diagnoses,	was	reported	to	be	
20%	 (Harris	 et	 al.,	 1991).	 Furthermore,	 a	 lack	 of	 established	 diagnostic	markers	 has	 also	






a	 (1)	 simple	 (≈20%)	 or	 (2)	 complex	 karyotype	 (≈80%)	 (Mertens	 et	 al.,	 2009).	 Simple	
karyotypes	 consist	 of	 specific	 mutations	 or	 chromosomal	 translocations	 that	 result	 in	
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oncogenic	fusion	proteins,	whereas	complex	karyotypes	are	characterized	by	aneuploidy,	as	











a	 painless	 mass	 that,	 based	 on	 its	 location,	 can	 impede	 organ	 function.	 It	 is	 the	 most	
commonly	occurring	soft	tissue	sarcoma	in	children	and	adolescents,	accounting	for	3%	of	
all	childhood	and	2%	of	all	adolescent	cancers	in	the	USA	(Ries	et	al.,	1999;	American	Cancer	












There	 are	 two	major	 subtypes	 of	 RMS	 based	 on	 their	 distinct	molecular	 and	 histological	
signatures:	embryonal	RMS	(ERMS)	and	alveolar	RMS	(ARMS).	The	remaining	RMS	subtypes	





in	a	myxoid	 stroma,	ARMS	 is	 characterized	by	clusters	of	 small,	 round,	blue	cells,	densely	





genetic	 aberrations	 such	 as	 loss	 of	 heterozygosity	 at	 chromosome	 11p15,	 a	 region	
harbouring	 the	 IGF2	 gene,	 and	 has	 a	 more	 favorable	 prognosis	 (Wang,	 2012;	 American	
Cancer	Society,	2014,	Chen	et	al.,	2013;	Hawkins	et	al.,	2014;	Shern	et	al.,	2014).	ARMS	on	
the	other	hand	occurs	 in	 adolescents	 and	young	adults,	 is	more	aggressive,	has	a	 greater	
rate	 of	 metastasis	 and	 recurrence	 and	 therefore	 a	 poorer	 prognosis	 (Parham	 &	 Ellison,	
2006;	Perez	et	al.,	2011;	Kikuchi	et	al.,	2014).	The	majority	of	ARMS	tumours	(80%)	contain	
the	 characteristic	 reciprocal	 translocations	 t(2;	 23)(q35;	 q14)	 or	 t(1;	 13)(q36;	 q14)	 which	
give	rise	to	the	chimeric	oncogenic	transcription	factors	PAX3-FKHR/FOXO1	(≈70%)	or	PAX7-
FKHR/FOXO1	 (≈10%)	 respectively	 (Figure	 1.5).	 The	 remaining	 20%	 are	 classed	 as	 being	
fusion-negative	 (Marshall	 &	 Grosveld,	 2012;	 Quesada	 &	 Amato,	 2012).	 The	 PAX	
transcription	 factors	 are	 involved	 in	 neural	 tube	 development	 and	 directing	 myoblast	











Figure	 1.5:	 The	 most	 prevalent	 chromosomal	 translocations	 in	 ARMS.	 Chromosomal	 translocation	 t(2;	








ERMS	 and	 ARMS,	 while	 genetically	 and	 histologically	 distinct,	 share	 a	 phenotype	 of	
incomplete	myogenic	 differentiation	 that	 contributes	 to	 oncogenesis.	 Interestingly,	 this	 is	
despite	 the	 expression	 of	 Myf5,	 MyoD,	 Myf6	 and	 myogenin	 which	 are	 the	 hierarchical	
factors	that	drive	muscle	development.	While	the	mechanism(s)	 involved	 in	RMS	 is	poorly	


































PAX3	 and	 c-Myc	 are	 expressed	 in	 RMS	 tumours	 and	 correlate	 with	 invasion,	 metastasis,	
resistance	 to	 anti-cancer	 drugs	 and	 poor	 overall	 survival	 (Walter	 et	 al.,	 2011;	 Sun	 et	 al.,	
2015).	
	
Microarray	 and	 comparative	 genomic	 hybridization	 array	 technologies	 in	 ERMS	 revealed	
that	 it	 is	 driven	 by	 a	 common	 set	 of	 genomic	 defects	 including	 the	 inactivation	 of	 the	
tumour	suppressors	p53,	p16,	p14,	p15INK4B	(CDKN2B),	PTEN	and	NF1	and	the	activation	or	
amplification	of	the	oncogenic	Ras,	Hh,	MDM1/2,	Gli1,	c-Met,	MYCN	and	FGFR1/4	(Merlino	
&	 Helman,	 1999;	 Paulson	 et	 al.,	 2011;	 Sun	 et	 al.,	 2015).	 Examples	 of	 how	 these	 defects	
contribute	to	rhabdomyosarcomagenesis	include	loss	of	NF1,	an	inhibitor	of	oncogene	Ras,	
allowing	 for	 increased	 proliferation,	 and	 amplification	 of	 MDM2,	 which	 interferes	 with	



















et	 al.,	 2014).	 In	 ARMS,	 PAX3/7-FKHR/FOXO1	 too	 was	 found	 to	 upregulate	 IGF	 and	 FGF	
signaling,	 as	 well	 as	 transcriptionally	 activate	 MET	 (c-Met),	 which	 in	 turn	 activates	 the	
Ras/Raf/MAPK	pathways	and	represses	downstream	cell	cycle	regulators	p19,	p21,	p53	and	
Rb		(Keller	&	Guttridge,	2013;	Wang,	2012;	Taulli	et	al.,	2006;	Taylor	et	al.,	2009;	Sun	et	al.,	
2015).	 Other	 deregulated	 growth	 factor	 pathways	 implicated	 in	 RMS	 include	 TGF-β,	
hepatocyte	growth	factor	(HGF)	and	platelet-derived	growth	factor	(PDGF).	Many	of	these	
signaling	 pathways	 converge	 on	 and	 inactivate	 negative	 regulators	 of	 the	 cell	 cycle	 to	
prevent	 cell	 cycle	 arrest	 required	 for	 terminal	 differentiation	 and	 thus	 enable	 tumour	






in	 ERMS,	mutations	 in	TP53	were	widespread	 and	 that	 the	Hedgehog	 and	Wnt	 pathways	
were	altered	(Chen	et	al.,	2013).	Moreover,	 in	a	pleomorphic	RMS	mouse	model	 in	which	
Ras	activation	was	combined	with	p53	inactivation,	Ras	was	shown	to	be	needed	for	tumour	
initiation	(Tsumura	et	al.,	2006).	This	 finding	 is	supported	by	another	study	 in	zebrafish	 in	
which	 constitutive	 Ras	 activation	 induced	 ERMS	 (Langenau	 et	 al.,	 2007).	 The	 authors	
reported	that	 in	this	study,	Ras	upregulated	the	anti-apoptotic	factors	MDM2	and	survivin	
that	 suppress	p53	as	well	 as	 the	muscle	progenitor	and	 satellite	 cell	 factors	MyoD,	Myf5,	
Myogenin,	Gli1	and	Notch1.	This	suggests	that	Ras	may	be	involved	in	proliferative	and	self-
renewal	pathways	in	ERMS.	Recently	it	was	also	found	that	activation	of	Ras	contributed	to	




was	 found	 to	 be	 altered	 in	 ERMS	 (Pressey	et	 al.,	 2011;	 Chen	et	 al.,	 2013;	Hawkins	et	 al.,	
2014;	Shern	et	al.,	 2014;	Satheesha	et	al.,	 2015).	Together	 this	 suggests	 that	Hh	signaling	
may	 too	 be	 a	 common	 feature	 in	 ERMS.	 Interestingly,	 during	 the	 development	 of	 the	
myotome,	 Hh	 signaling	 is	 needed	 for	 cell	 survival	 and	 proliferation	 through	 suppressing	
apoptosis	 (Belyea	 et	 al.,	 2012).	 Furthermore,	 Ptch1,	 Gli1,	 Gli3,	 and	 Myf5,	 downstream	
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between	self-renewal	and	differentiation	as	 it	mediates	cell	 fate	determination	 (Belyea	et	
al.,	2012).	In	both	RMS	subtypes	it	is	thought	to	inhibit	myogenesis,	maintain	stem-ness	and	
regulate	 motility	 and	 invasiveness	 (Roma	 et	 al.,	 2012;	 Belyea	 et	 al.,	 2012).	 Moreover,	
inhibiting	 Notch	 in	 RMS	 resulted	 in	 activation	 of	 p21,	 myotube	 differentiation	 and	
hampered	tumour	growth	in	vitro	and	in	vivo	(Raimondi	et	al.,	2012;	De	Salvo	et	al.,	2014).	
In	 development,	 Wnt	 signaling	 regulates	 embryonic	 somite	 patterning	 and	 myogenesis	
through	the	processes	of	proliferation,	cell	migration,	polarity	and	cell	death	(Annavarapu	et	
al.,	 2013).	 Not	 surprisingly,	 its	 deregulation	 contributes	 to	 invasion	 and	 metastasis	 of	
various	 cancers.	 Interestingly,	 while	 Annavarapu	 et	 al.	 (2013)	 reported	 that	 the	 Wnt/β-
catenin	 signaling	 pathway	was	 functionally	 active	 in	 a	 significant	 subset	 of	 RMS	 tumours,	
there	 is	 debate	 as	 to	 whether	 it	 plays	 an	 anti-oncogenic	 or	 pro-oncogenic	 role	 in	 RMS.	
Indeed,	 there	have	been	 reports	 that	Wnt	may	 repress	proliferation	and	promote	muscle	





Finally,	 during	 development	 Hh,	 Wnt	 and	 Notch	 signaling	 function	 in	 the	 expansion	 of	
muscle	stem	cell	subpopulations	and	their	aberrant	expression	is	associated	with	persistent	











lymph	nodes	or	distant	sites	 (Malempati	&	Hawkins,	2012).	Treatments	 for	RMS	 include	a	
combination	 of	 surgery,	 radiation	 and	 chemotherapy	 and	 while	 prognosis	 has	 improved,	
from	 approximately	 25%	 in	 1970	 to	 75%	 today,	 there	 is	 a	 strong	 drive	 to	 identify	 more	
effective	targeted	therapeutics,	for	example,	based	on	the	molecular	and	genetic	profile	of	
a	tumour	(Malempati	&	Hawkins,	2012).	A	chemical	screen	for	drugs	to	repress	proliferation	
and	 self-renewal	 in	 ERMS	 identified	 inhibitors	 of	 glycogen	 synthase	 kinase	 3	 (GSK3)	 (a	
repressor	of	myogenin),	Raf/MEK,	PI3K/AKT,	Hh,	HDACs	and	DNA	damaging	agents	(Chen	et	
al.,	 2014).	 At	 the	 moment	 popular	 targeted	 therapies	 for	 RMS	 include	 mTOR	 and	 Hh	
inhibitors	and	RTK	specific	monoclonal	antibodies	or	 small-molecule	 inhibitors	 (see	 Figure	
1.6).	 However,	 although	 an	 initial	 response	may	 be	 observed	with	 these	 treatments,	 the	
disease	 often	 continues	 to	 progress	 and/or	 tumour	 drug	 resistance	 develops.	 Furthering	
targeted	 therapies	 requires	 improved	molecular	 classifications	and	diagnoses	 for	accurate	
targeting,	as	well	as	greater	identification	of	master	differentiation	transcription	factors,	cell	
cycle	regulators	and	mitogenic	signaling	pathways	that	are	altered	in	RMS.	While	ERMS	has	
a	 better	 prognosis	 compared	 to	 ARMS,	 a	 plateau	 in	 effectiveness	 of	 current	 treatments	
(70%	 five-year	 survival	 rate)	 has	 been	 reached	 despite	 newer	 and	 more	 intensive	








offer	 potential	 for	 targeted	 therapeutic	 intervention.	 The	 diversity	 of	 targets	 and	 multitude	 of	 agents	
illustrates	 the	 need	 to	 leverage	 model	 systems	 to	 focus	 clinical	 trial	 efforts	 in	 the	 small	 RMS	 patient	
population.	 The	 drugs	 that	 target	 different	 signaling	 pathways	 are	 listed	 in	 boxes	 adjacent	 to	 the	
corresponding	 proteins,	whereas	 other	 targets	 are	 listed	 in	 an	 independent	 box.	 ALK,	 anaplastic	 lymphoma	
kinase;	 ANG1,	 angiopoietin	 1;	 BAD,	 BCL-2-associated	 agonist	 of	 cell	 death;	 CCND,	 cyclin	 D;	 CDK,	 cyclin-
dependent	 kinase;	 CTLA4,	 cytotoxic	 T	 lymphocyte-associated	 antigen	 4;	 EGFR,	 epidermal	 growth	 factor	
receptor;	FGFR4,	fibroblast	growth	factor	receptor	4;	FOXO1;	forkhead	box	O1;	GSK3,	glycogen	synthase	kinase	
3;	HDAC,	histone	deacetylase;	 IGF1R,	 insulin-like	growth	factor	1	receptor;	NICD,	Notch	 intracellular	domain;	
NF1,	neurofibromin	1;	PAX,	paired	box;	PD1,	programmed	cell	death	protein	1;	PDGFR,	platelet-derived	growth	
factor	 receptor;	 PLK1,	 Polo-like	 kinase	 1;	 PTCH,	 Patched;	 RB1,	 retinoblastoma	1;	 RBPJ,	 recombination	 signal	













objective	 of	 this	 study	 is	 to	 explore	 the	 significance	 of	 TBX3	 overexpression	 on	 the	
oncogenic	phenotype	of	ERMS.	This	will	be	achieved	through	establishing	ERMS	cell	culture	
models	 in	which	TBX3	 is	either	 stably	knocked	down	or	overexpressed	and	 the	effects	on	
key	hallmarks	of	the	cancer	phenotype	will	be	investigated.	It	is	hypothesized	that	whereas	





Aim	 1:	 To	 stably	 knock-down	 TBX3	 in	 ERMS	 cells	 that	 express	 high	 levels	 of	 this	 protein	






Aim	 3:	 To	 perform	 preliminary	 experiments	 to	 characterise	 protein	 co-factors	 that	 co-
operate	with	TBX3	to	drive	its	oncogenic	activity	in	ERMS.	
	










et	 al.,	 1989).	 The	 pSuper.neo/GFP	 vectors,	 either	 containing	 a	 shRNA	 specific	 to	 TBX3	
(SHTBX3)	or	a	non-specific	 scramble	 shControl	 (SHCTRL)	 sequence	were	previously	 cloned	




expression	 constructs	 for	 Tbx3	 harbouring	 a	 5’-3XFLAG	 tag	 was	 kindly	 provided	 by	 our	
collaborator	Colin	Goding	(Ludwig	Institute,	University	of	Oxford,	UK).	The	pEGFP-C1	vector	
containing	 full	 length	 GFP-nucleolin	 was	 purchased	 from	 Addgene	 (plasmid	 #28176)	 and	








Transfection	 is	 the	 process	 whereby	 cells	 take	 up	 and	 express	 exogenous	 DNA	 or	 RNA	
(Figure	 2.1).	 Prior	 to	 performing	 transfections,	 the	 concentration	 and	 quality	 of	 DNA	 of	
constructs	 were	 assessed	 using	 a	 NanoDrop	 ND-100	 spectrophotometer	 (Agilent	
Technologies,	Boeblingen,	Germany)	and	the	integrity	of	the	DNA	confirmed	by	agarose	gel	
electrophoresis.	 In	 general	 transfection	 reagents	 are	 lipid	 based	 therefore	 allowing	 for	








plated	 at	 4	 x	 105	 per	well	 of	 a	 12-well	 plate	 (3.5	 x	 104	 per	well	 of	 a	 24-well	 plate)	 1	 day	
before	transfection.	Three	microliters	 (1.5	μl	 for	24-well	plate)	of	the	transfection	reagent	
was	 added	 to	 97	 μl	 (48	 μl	 for	 24-well	 plate)	 serum	 free	medium	 and	 incubated	 at	 room	




lines:	 Cells	 at	 60-70%	 confluence	 in	 35mm	 dishes	 were	 transfected	 with	 1	 μg	 of	
















sic-Myc	 (Dharmacon,	 Lafayette,	 CO,	 USA	 and	 Qiagen,	 USA),	 50nM	 siNuc	 (SI02654925,	








RD	cells	 express	high	 levels	 of	 TBX3	and	were	 therefore	 selected	 to	 generate	 cell	 lines	 in	
TBX3	mRNA	and	protein	levels	were	stably	knocked	down.	Cells	were	transfected	with	the	
pSuper.neo/GFP-shTBX3	 or	 -shCtrl	 expression	 vectors	 using	 Fugene®	 (Bio-Rad,	 USA)	 as	





RD	 cells	 were	 transfected	 with	 either	 3XFLAGpCMV-mtbx3,	 3XFLAGpCMV-mtbx3+2a	 or	
3XFLAGpCMV-Empty	expression	vectors	using	FuGENE	as	described	in	section	2.2.1.1.	Stably	





Human	 embryonic	 rhabdomyosarcoma	 (ERMS)	 RD	 cells	 were	 purchased	 from	 American	
Tissue	 Culture	 Collection	 (ATCC).	 Cells	 were	 maintained	 in	 Dulbecco’s-modified	 Eagle	
medium	 (DMEM)	 (Sigma	Aldrich,	 USA)	 supplemented	with	 10%	 fetal	 bovine	 serum	 (FBS),	
100	 U/ml	 penicillin	 and	 100	 µg/ml	 streptomycin.	 Cells	 were	 maintained	 at	 37°C	 in	 an	
atmosphere	 of	 5%	 CO2	 and	 65%	 humidity.	 Sterile	 technique	 was	 practiced,	 media	 was	





Figure	 2.1:	siRNA,	 shRNA	and	 expression	 vector	 processing	 and	 action.	 Transfection	of	expression	vectors,	
shRNA	 and	 siRNA.	 Expression	 vectors	 (top)	 are	 able	 to	 enter	 into	 a	 host	 cell’s	 nucleus	where	 it	 co-opts	 its	
protein	synthesis	machinery	to	express	its	own	gene	of	interest	off	its	promoter.	shRNA	vectors	(middle)	also	
enter	 into	a	host	cell’s	nucleus	but	are	able	 to	 integrate	 into	 it	genome	and	 thereby	expressed	 through	 the	
cell’s	natural	transcription	and	translation	process,	ultimately	producing	a	single-stranded	RNA	molecule	that	






Mycoplasma	 tests	 were	 performed	 to	 ensure	 that	 uninfected	 cells	 were	 used	 in	
experiments.	 	 Mycoplasma	 are	 parasitic	 bacteria	 that	 have	 no	 cell	 walls.	 These	 micro-
organisms	have	very	 limited	biosynthetic	capabilities	and	therefore	rely	on	their	host	cells	
for	 survival	 and	 replication.	Mycoplasma	 can	 have	 deleterious	 effects	 on	 their	 host	 cells,	














inhibiting	 apoptosis,	 altering	 cell	 morphology,	 DNA,	 RNA	 and	 protein	 synthesis,	 and	 cell	
growth	 and	 even	mediating	 cancerous	 transformation	 (Rottem	et	 al.,	 2012).	Mycoplasma	
can	be	detected	using	 a	 nucleic	 acid	 stain,	Hoescht,	which	detects	 both	mycoplasma	and	





Cells	 were	 viewed	 under	 a	 fluorescent	 microscope	 using	 the	 DAPI	 filter.	 Mycoplasma	







pCMV	 and	 pSuper.neo/GFP	 expression	 vectors	 containing	 the	 TBX3	 overexpression,	 TBX3	
knock-down	 and	 control	 sequences,	 carry	 a	 neomycin	 resistance	 gene.	 G-418	 is	 an	
aminoglycoside	 antibiotic	 that	 alters	 normal	 protein	 production	 by	 inhibiting	 polypeptide	




well	 plate	 and	when	 the	 cells	were	 approximately	 60%	 confluent	 they	were	 treated	with	
various	 concentrations	 of	 G-418,	 ranging	 from	 0	 –	 1.2	 mg/ml,	 and	 monitored	 daily.	 The	
lowest	concentration,	0.8	mg/ml,	which	resulted	in	complete	cell	death	after	approximately	











S-phase	 by	 a	 double	 thymidine	 (Sigma,	 USA)	 block	 (15	 hours	 2	 mM	 thymidine,	 9	 hours	
release,	15	hours	thymidine	and	a	4	hour	release	by	3	brief	washes	with	fresh	media	and	the	





To	 inhibit	the	kinase	activity	of	AKT	 in	RD	cells	4	x	104	cells	were	plated	 in	a	24-well	plate	






To	assess	 the	 levels	of	 TBX3	mRNA	 in	 the	 stable	overepxression,	 knock-down	and	 control	
cell	 lines	quantitative	 real-time	polymerase	chain	 reaction	 (qRT-PCR)	was	performed.	RNA	
was	 harvested,	 purified,	 and	 converted	 to	 complementary	 DNA	 (cDNA).	 Forward	 and	












70-80%	 confluence,	 after	 two	 chilled	 1X	 Phosphate	 Buffered	 Saline	 (1X	 PBS)	washes	 (see	
Appendix	section	6.3),	using	400	μl	per	dish	of	High	Pure	RNA	Isolation	Kit	Lysis	Buffer.	The	
Lysis	Buffer	contains	Triton-X	100	detergent	to	permeabilize	the	cell	membranes,	Tris-HCl,	
to	 regulate	 pH	 and	 osmolarity	 of	 the	 lysate,	 and	 guanidine	 hydrochloride,	 to	 denature	
proteins,	 inactivate	RNases	and	promote	binding	of	the	RNA	to	the	membrane	of	the	spin	
column.	 Extraction	 was	 performed	 according	 to	 the	 manufacturer’s	 instructions.	 Briefly,	
genomic	 DNA	was	 removed	 via	 addition	 of	 the	 supplied	 deoxyribonucleases	 (DNase)	 and	
DNase	 incubation	buffer	 followed	by	 centrifugation.	 The	phosphodiester	 backbone	of	 the	
DNA	 was	 hydrolytically	 cleaved	 and	 the	 degraded	 DNA	 removed	 by	 washes	 and	
centrifugation,	leaving	behind	the	RNA.	The	RNA	was	eluted	in	nuclease	free	double	distilled	
water.	The	wash	buffers	and	centrifugation	steps	remove	proteins,	 lipids,	polysaccharides,	
salts	and	other	cellular	 impurities	 from	the	RNA	solution	and,	during	the	elution	step,	 the	
polarity	of	the	water	disrupts	the	bonds	between	the	RNA	and	membrane,	enabling	elution.	











mM	 dNTP	mix,	 20	 units	 RNasin®	 ribonuclease	 inhibitor	 and	 1	 μl	 of	 ImProm-IITM	 reverse	
transcriptase)	to	a	final	volume	of	20	μl.	The	annealing	of	the	primers	to	the	template	RNA	
occurred	 at	 25oC	 for	 5	minutes,	 the	 reactions	were	 incubated	 at	 42oC	 for	 1	 hour	 for	 the	
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μl	 of	 combined	 forward	 and	 reverse	 primers	 (10	μM)	 per	 18	μl	 reaction	 or	 2X	 Kapa	Mix,	
Sabax	 H2O,	 2.5	 μg/μl	 bovine	 serum	 albumin	 (BSA)	 and	 0.4	 μl	 of	 combined	 forward	 and	
reverse	primers	(10	μM)	per	9	μl	reaction.	PCR	reactions	were	made	up	as	master	mixes	and	
aliquoted	into	glass	capillaries	with	the	addition	of	2	μl	or	1	μl	of	cDNA	per	capillary	to	give	a	
final	 reacion	 volume	 of	 20	 μl	 or	 10	 μl	 for	 the	 SensiMix	 and	 KAPA	 SYBR	 FAST	 reactions	
respectively.	 Primers	 specific	 to	 TBX3	 (QT00022484,	 Qiagen,	 Germany),	 c-Myc,	 and	
Glucuronidase	Beta	 (GUSB)	 (QT00046046,	Qiagen,	Germany),	 for	 internal	normalisation	 to	
correct	 for	 sample-to-sample	variations	within	a	PCR	 run,	were	used.	The	glass	 capillaries	
were	 centrifuged	 at	 3000	 rpm	 for	 1	 minute	 and	 placed	 in	 the	 LightCycler	 3.0	 (Roche,	
Switzerland).	PCR	cycle	parameters	were:	denaturation	(15	minutes	at	95oC),	annealing	and	
amplification	for	35	cycles	(5	seconds	at	95oC;	3	seconds	at	55oC;	5	seconds	at	72oC),	melting	




Relative	mRNA	 expression	 levels	were	 normalized	 to	 glucuronidase	 beta	 (GUSB)	 for	 each	
reaction	 with	 PCR	 efficiency	 correction	 calculated	 using	 the	 formula	 Ratio	 =	
(Etarget)CPtarget(control–sample)/(Eref)CPref(control–sample);	E:	 real-time	PCR	efficiency,	
CP:	 crossing-point.	 The	Microsoft	 Excel	 programme	was	 used	 to	 calculate	 the	 statistically	










dish,	were	centrifuged	at	2500	rpm	for	2	minutes,	 the	media	discarded	and	 the	pellet	 re-
suspended	in	70ul	of	boiling	blue	buffer	(see	Appendix	section	6.3).	Alternatively,	the	cells	
were	 lysed	 in	 adjusted	 volumes	 of	 boiling	 blue	 buffer,	 according	 to	 the	 dish	 area	 and	







with	 a	 5%	 stacking	 gel	 (see	 Appendix	 section	 6.3).	 Gels	 were	 assembled	 in	 Biorad	Mini	
PROTEAN©	3	casting	apparatus,	placed	 in	 the	Biorad	 running	 tank	and	 the	 tank	was	 filled	
with	1X	running	buffer	(see	Appendix	section	6.3).	Equal	amounts	of	sample	(10-20	μl)	were	
loaded	and	6	μl	 of	 PageRuler	 Prestained	Protein	Marker	 (Fermentas,	USA)	 (see	 Appendix	
section	6.3)	was	also	 loaded	 to	determine	 the	 relative	 size	of	 the	proteins	 (see	 Appendix	





Electrophoresed	 proteins	 were	 transferred	 onto	 nitrocellulose	 blotting	 membrane	
(Amersham,	 GE	 Healthcare,	 Life	 Sciences,	 Germany).	 Gels	 were	 placed	 in	 a	 transfer	
‘sandwich’	 cassette	 consisting	 of	 sponges,	 whatman	 filter	 paper,	 the	 gel	 and	 the	
nitrocellulose	membrane	 presoaked	 in	 1X	 transfer	 buffer	 (see	 Appendix	 section	 6.3)	 and	
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assembled	 into	 the	 correct	 order	 (Figure	 2.2).	 This	 cassette	 was	 then	 placed	 into	 the	















Following	 transfer,	 membranes	 were	 blocked	 for	 1	 hour	 at	 RT	 with	 1X	 PBS/0.1%	 Tween	
(PBS/T)	 (see	 Appendix	 section	 6.3)	 containing	5%	non-fat	dry	milk	 (see	 Appendix	 section	
6.3)	and	probed	with	appropriate	primary	antibodies	overnight	at	4oC	with	shaking.	Primary	











Zymed,	 San	 Francisco,	 CA)	 or	 (1:1000)	 (ab99302,	 Abcam,	USA),	 rabbit	 polyclonal	 anti-p38	






secondary	 antibody,	 horseradish	 peroxidase-conjugated	 anti-rabbit	 (1:5000)	 (BioRad,	
Hercules,	 CA,	 USA),	 horseradish	 peroxidase-conjugated	 anti-mouse	 (1:5000)	 (BioRad,	
Hercules,	CA,	USA)	or	A/G	protein	(1:5000)	(20421,	Thermo	Fisher	Scientific),	for	1	hour	at	
RT,	 then	 washed	 four	 times	 as	 previously	 described,	 before	 protein	 detection	 was	
performed	and	visualised	by	enhanced	chemiluminescence	(ECL)	by	addition	of	SuperSignal	
West	 Pico	 Chemilumninescent	 Substrate	 (Pierce,	 Rockford,	 IL,	 USA)	 or	 WesternBright	
(Advansta,	USA)	(Figure	2.3).	Equal	amounts	of	detection	reagent	A	and	detection	reagent	B	
were	used	per	blot	and	allowed	to	incubate	on	the	membrane	for	5	minutes	before	being	
enclosed	between	 two	acetate	 sheets.	 The	 substrate	 for	horseradish	perioxidase	 is	 found	
within	the	detection	reagent	and	therefore	oxidation	of	the	substrate	is	catalysed	when	the	
detection	 reagents	 comes	 into	 contact	 with	 the	 enzyme	 conjugated	 secondary	 antibody;	
leading	 to	 the	 emission	 of	 light	 (Figure	 2.3).	 Membranes	 were	 exposed	 to	 x-ray	 film	
(autorad)	 and	 the	 resulting	 chemiluminscent	 signal	 captured	by	developing	 and	 fixing	 the	





Figure	 2.3:	 Western	 Blot	 detection	 by	 chemiluminescence.	 The	 primary	 antibody	 raised	 against	 its	 target	
protein	 will	 bind	 to	 it	 if	 present	 on	 the	 membrane	 blot	 containing	 the	 transferred	 proteins.	 An	 enzyme-





























(dehydrogenases)	 are	 active.	 The	 purple	MTT	 formazan	 crystals	 are	 insoluble	 in	 aqueous	
solutions,	 therefore	 a	 solubilizing	 solution,	 containing	 acidified	 isopropabol,	 is	 able	 to	
dissolve	the	crystals	into	a	purple	solution,	which	is	then	spectrophotometrically	measured.	
Therefore	the	number	of	viable	cells	 is	directly	related	to	a	sample’s	ability	to	convert	the	









the	manufacturer’s	 instructions	 (11465007001,	Roche).	Briefly,	 cells	were	allowed	to	grow	
for	 48	 hours	 prior	 to	 adding	 10	 μl	 of	 pre-warmed	MTT	 labelling	 reagent	 (0.5	mg/ml)	 per	
well,	incubated	at	37oC	for	4	hours,	after	which	100	μl	of	pre-warmed	solubilisation	solution	
was	added	per	well	and	incubated	at	37oC	overnight.	The	spectrophotometrical	absorbance	



























To	 determine	 the	 effect	 overexpressing	 and	 knocking	 down	 TBX3	 has	 on	 anchorage	
independent	growth,	soft	agar	assays	were	performed.	If	a	cell	does	not	need	anchorage	to	
grow	then	it	will	be	able	to	proliferate	and	form	colonies,	small	clusters	of	cells,	which	can	
be	 stained	 and	 viewed	 with	 the	 naked	 eye	 or	 under	 the	 microscope.	 However,	 if	 a	 cell	






to	 prevent	 cells	 from	 attaching	 to	 the	 bottom	 of	 the	 dish.	 Dishes	were	 incubated	 at	 4oC	
overnight	to	allow	the	agar	to	solidify.	Cells	were	resuspended	in	0.35%	agar/medium	slurry	
and	plated	on	 top	of	 the	 0.5%	agar/medium	 layer	 at	 a	 concentration	of	 3	 x	 104	 cells	 per						






















through	 the	 cell	 monolayer	 using	 a	 sterile	 20	 μl	 pipette	 tip.	 To	 remove	 cell	 debris,	 the	
growth	 medium	 was	 removed	 and	 then	 replaced,	 and	 to	 prevent	 cell	 proliferation	
Mitomycin	C	 (Sigma,	USA)	was	 added	 at	 a	 final	 concentration	of	 5	μg/ml.	Markings	were	
made	across	the	scratch	 line	as	reference	points	 for	photograph	taking	to	ensure	that	the	
same	 area	 of	 the	 scratch	 was	 measured	 throughout	 the	 assay.	 The	 wound	 area	 was	
measured	at	the	time	of	the	scratching	(0	hour)	and	thereafter	at	3	hour	intervals	until	the	
ninth	or	twelfth	hour	timepoint	(Figure	2.6).	Pictures	were	taken	using	a	non-phase	contrast	


















In	 vivo	 tumour	 formation	was	 assayed	by	 subcutaneously	 injecting	 cultured	 cells	 into	 the	
right	 flanks	of	4-6	week	old	UCT	21	 (MF1	athymic/immunocompromised)	nude	mice	bred	
and	acquired	at	UCT’s	animal	unit	BCL2.	3	x	106	RD	or	1	x	107	Flag	Empty	and	Flag-mtbx3+2a		
cells	 were	 resuspended	 in	 100	 μl	 sterile	 1X	 PBS	 and	 injected	 into	 both	male	 and	 female	
mice.	 7	 mice	 were	 used	 for	 each	 cell	 line.	 Mice	 were	 maintained	 in	 pathogen-free	
environments	and	were	monitored	daily	for	tumour	formation.	For	ethical	reasons,	all	mice	
were	 humanely	 euthanised	 using	 halothane	 after	 6	 weeks.	 Mice	 were	 subjected	 to	
autopsies	and	the	presence	of	metastatic	tumours	was	investigated	by	visual	assessment	of	
the	organs	such	as	the	lungs,	liver	and	bone.	All	animal	experiments	were	approved	by	the	
Institutional	 Committee	 on	 Ethics	 of	 Animal	 Experimentation	 (protocol	 number	 AEC	
015/027).		
	




















stained	by	 incubating	 the	cells	with	0.5	μg/ml	Hoechst	33258	 for	10	minutes	at	RT	 in	 the	
dark.	Cells	were	washed,	the	coverslips	mounted	onto	glass	slides	using	Mowial	mounting	
medium	 (Hoechst,	Germany)	 containing	 n-Propyl	 gallate	 (anti-Fade)	 (Sigma,	USA)	 and	 the	
cells	were	visualised	by	a	confocal	microscope	(Zeiss	LSM	510	Meta	with	NLO,	Software:	ZEN	
2009,	Lasers:	Argon	488	green,	solid	state	laser:	561	nm	Red,	MaiTai	2	photon	laser:	750	nm	
for	 DAPI/	 Hoechst,	 Germany)	 (Figure	 2.7).	 Negative	 controls	 were	 the	 appropriate	
secondary	antibodies	only.	Co-localisation	analysis	to	obtain	values	for	Mander’s	coefficient,	












Paraffin-embedded	 tissue	 sections	 were	 obtained	 from	 the	 Division	 of	 Anatomical	
Pathology,	 University	 of	 Cape	 Town	 and	 this	 study	 was	 approved	 by	 and	 performed	 in	
accordance	with	the	University	of	Cape	Town	Human	Research	Ethics	Committee.	Paraffin-
embedded	 tumour	 tissues	 from	 surgical	 specimens	 (before	 chemotherapy)	were	 cut	 in	 5	
μm-thick	 sections	 and	 placed	 on	 superfrost	 charged	 slides.	 The	 tissue	 sections	 were	
deparaffinised	 in	 three	 changes	 of	 xylol	 and	 hydrated	 through	 graded	 ethanol	 series	
(absolute	 ethanol	 –	 96%	 ethanol	 –	 70%	 ethanol	 –	 50%	 ethanol).	 Antigen	 retrieval	 was	
performed	with	citric	acid	buffer	at	pH	6	for	90	seconds	using	a	pressure	cooker	and	cooled	
for	 an	 additional	 30	minutes.	 Endogenous	 peroxidase	was	 quenched	 by	 incubation	 in	 3%	
methanol/H2O2	for	10	minutes.	Tissue	sections	were	blocked	with	5%	goat	serum	(X090710,	
Dako,	 Denmark)	 in	 PBS	 and	 incubated	 with	 rabbit	 polyclonal	 anti-TBX3	 (1:25;	 Zymed,	
Invitrogen,	 Carlsbad,	 CA)	 overnight.	 Goat	 anti-rabbit	 Envision	 reagent	 (K400211,	 Dako,	
Denmark)	was	applied	for	30	minutes.	The	chromogenic	substrate	was	applied	(1ml	buffer	+	
1	 drop	 DAB)	 for	 10	minutes	 (K346711,	 Dako,	 Denmark).	 Slides	were	 rinsed	 in	water	 and	
counterstained	with	haematoxylin	 for	 1	minute.	Nuclei	were	 stained	with	 Scott’s	 solution	
























Flag-Empty,	 Flag-mtbx3	 or	 Flag-mtbx3+2a	 RD	 cells	 were	 grown	 in	 15	 cm	 dishes	 to	 90%	
confluence	 and	 harvested	 in	 1ml	 of	 lysis	 buffer	 (see	 Appendix	 section	 6.4).	 Cells	 were	
incubated	for	30	minutes	on	a	shaker	at	4°C,	sonicated	on	 ice	for	3	x	30	seconds,	with	10	
second	breaks	in	between,	and	cellular	debris	removed	by	centrifugation	at	12	000	rpm	for	
10	 minutes	 at	 4°C.	 The	 supernatant	 was	 incubated	 with	 40	 μL	 of	 anti-Flag	 antibody	
conjugated	 to	 agarose	 beads	 pre-equilibrated	 in	 1X	 TBS	 buffer	 (anti-Flag	M2	 affinity	 gel,	
A2220,	 Sigma)	 with	 constant	 rotation	 for	 overnight	 at	 4°C.	 Following	 binding,	 protein-

















lysates	 and	 incubated	 at	 4°C	 with	 rotation	 overnight.	 The	 immune	 complexes	 were	
immunoprecipitated	with	20	μl	of	protein	A/G	Sepharose	beads	at	4°C	with	rotation	 for	4	
hours,	 washed	 in	 cold	 1X	 PBS	 four	 times,	 boiled	 in	 40	 μl	 boiling	 blue	 loading	 buffer	 and	
protein	 samples	 were	 analysed	 by	 SDS-PAGE	 and	 western	 blotting	 using	 antibodies	 to	
nucleolin	(1:1000)	(sc-8031),	Hsc70	(1:1000)	(sc-7298,	Santa	Cruz	Biotechnology,	Santa	Cruz,	




Figure	 2.8:	 Flag	 affinity	 purification	 and	 immunoprecipitation	 assays.	 Immunoprecipitation	 assays	 aim	 to	
reveal	protein-protein	 interactions	 through	pulling	down	one	protein,	 “Y”,	 and	 then	western	blotting	 for	 its	







performed	 using	 the	 2-sample	 t-test	 (Microsoft	 Excel	 software)	 and	 p<0.05	 (*)	 was	




























western	blotting	 revealed	 that,	 relative	 to	normal	 cell	 lines,	 TBX3	 is	 overexpressed	at	 the	
mRNA	 and	 protein	 levels	 in	 cell	 lines	 representative	 of	 chondrosarcoma,	 fibrosarcoma,	
liposarcoma,	 synovial	 sarcoma	and	embryonal	 rhabdomyosarcoma	 (ERMS)	 (Fig.	 3.1A	&	B;	
taken	from	Willmer	et	al.,	2016).	While	two	PhD	students	in	the	Prince	laboratory	followed	
up	 on	 the	 role	 of	 TBX3	overexpression	 in	 chondrosarcoma	 and	 fibrosarcoma,	 the	 current	
study	investigated	the	role	of	TBX3	in	ERMS.	To	this	end,	cell	culture	models	in	which	TBX3	
was	stably	knocked	down,	or	further	overexpressed,	in	the	RD	ERMS	cell	line	were	created	
and	 analyses	 conducted	 by	 performing	 a	 number	 of	 in	 vitro	 and	 in	 vivo	 transformation	





its	 oncogenic	 role	 in	 ERMS	 was	 investigated.	 Both,	 Hsc70	 and	 nucleolin	 were	 shown	 to	
interact	and	co-localise	with	TBX3	in	ERMS	cells	and	nucleolin	was	shown	to	co-operate	with	











a	panel	of	 soft	 tissue	and	bone	sarcoma	cell	 lines	 including	 the	human	ERMS	cell	 line,	RD	
(Fig.3.1A	&	 B,	 taken	 from	Willmer	et	 al.,	 2016).	 To	determine	 the	 status	 of	 TBX3	protein	
levels	in	archival	patient-derived	rhabdomyosarcoma	tissue	sections	immunohistochemistry	





2007;	 Hoogaars	 et	 al.,	 2004b).	 Indeed	 nuclear	 TBX3	 staining	 was	 observed	 in	 these	
structures	 indicating	 that	 the	 TBX3	 antibody	 is	 specific	 (Fig.3.1C).	 Compared	 to	 normal	




3.2	 Establishment	 and	 characterization	 of	 human	 embryonal	
rhabdomyosarcoma	 (ERMS)	 cell	 lines	 in	 which	 TBX3	 was	 stably	
knocked	down	or	overexpressed		
	
According	 to	 Hanahan	 &	 Weinberg	 (2011)	 the	 6	 key	 hallmarks	 of	 cancer	 are:	 (1)	
constitutively	active	proliferative	signaling,	 (2)	evasion	of	growth	suppressors,	 (3)	 resisting	
cell	 death,	 (4)	 replicative	 immortality,	 (5)	 inducing	 angiogenesis	 and	 (6)	 activation	 of	
invasion	and	metastasis.	We	hypothesized	that	knocking	down	TBX3	in	ERMS	may	reverse,	
at	 the	 very	 least,	 some	 of	 these	 hallmarks	 whereas	 further	 overexpressing	 TBX3	 may	
enhance	 the	 cancer	 phenotype.	 Therefore,	 this	 study	 investigated	 the	 consequences	 of	
either	stably	knocking	down,	using	a	short-hairpin	RNA	(shRNA)	approach,	or	overexpressing	
TBX3	 in	 RD	 cells	 on	 their	 cellular	 morphology,	 cell	 proliferation,	 anchorage	 independent	
growth	 and	migration,	 and	 tumour	 formation	 in	 nude	mice.	Whereas	 the	 shRNA	method	
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Before	 cell	 culture	 models	 could	 be	 established	 RD	 cells	 were	 tested	 for	 the	 parasitic	
bacteria,	 mycoplasma,	 to	 ensure	 that	 only	 mycoplasma	 free	 cells	 were	 used	 for	 further	
analyses	 (data	 not	 shown).	 This	 is	 important	 because	 mycoplasma	 can	 have	 deleterious	
effects	 on	 their	 host	 cells,	 including	 affecting	 their	 signal	 transduction	 pathways	 and	




The	 following	 constructs,	 already	 available	 in	 the	 laboratory,	 were	 used	 to	 establish	 the	
knock-down	 and	 overexpression	 cell	 culture	 models:	 the	 pSuper.neo/GFP	 containing	 a	
shTBX3	sequence	 targeting	TBX3	 (SHTBX3)	or	a	 scrambled	control	 sequence	 (SHCTRL)	and	
the	 pCMV	 expression	 vector	 containing	 the	 Flag-mtbx3,	 Flag-mtbx3+2a	 or	 Flag	 Empty	
control	 sequence.	 All	 these	 constructs	 carry	 the	mammalian	 neomycin	 gene	 that	 confers	




























are	 the	 cells	 undergoing	 epithelial-to-mesenchymal	 transition?	 The	 microscopic	 images	
shown	in	Figure	3.3	indicate	that	there	were	no	notable	differences	in	cell	morphology	seen	
across	any	of	 the	cell	 lines	when	TBX3	was	depleted.	 Indeed,	 throughout	all	experimental	
analyses,	 they	 displayed	 an	 elongated,	 bipolar	 and	 multipolar,	 spindle-shaped	 cell	
morphology	characteristic	of	RD	cells.		
	




proliferate	 in	 a	 chronic,	 uncontrolled	 fashion.	 Therefore	 the	 next	 set	 of	 experiments	
investigated	 the	 effect	 of	 knocking	 down	 TBX3	 on	 cell	 proliferation.	 Short-term	 cell	
proliferation	 was	 measured	 by	 the	 methylthiazol	 tetrazolium	 (MTT)	 assay,	 using	
mitochondrial	activity	as	a	proxy	for	cell	viability	and	proliferation.	In	this	assay	the	number	
of	living	cells	present	is	related	to	their	ability	to	reduce	yellow	tetrazolium	salt	into	purple	





The	 possibility	 was	 considered	 that	 while	 TBX3	 may	 have	 no	 significant	 effect	 on	 cell	
proliferation	over	a	48-hour	time	course	it	may	impact	long-term	cell	proliferation.	Growth	






profile	 of	 SHCTRL	 and	 SHTBX3	 cell	 lines	 cultured	 in	 standard	 10%	 FBS	 using	 fluorescence	
assisted	cell	sorting	(FACS).	The	results	show	that	the	SHCTRL	and	SHTBX3	(1)	cells	exhibited	
a	 profile	 typical	 of	 dividing	 cells	 (Fig.3.4C	 &	 D).	 Interestingly,	 the	 SHTBX3	 (2)	 cell	 line	
displayed	an	increased	percentage	of	apoptotic	and	S-phase	cells	(Fig.3.4E)	which	provides	
support	 for	 previous	 studies	 showing	 that	 TBX3	 promotes	 cancer	 cell	 survival	 through	 its	
ability	to	evade	apoptosis	 (Renard	et	al.,	2007).	 In	addition,	the	Prince	 laboratory	has	also	









(2%	 FBS)	medium,	 compared	 to	 10%	 FBS	medium,	was	 investigated.	 Figure	 3.4F	 shows	 a	
significant	 decrease	 in	 proliferative	 rates	 of	 both	 SHTBX3	 (1)	 and	 SHTBX3	 (2)	 cell	 lines	
relative	to	SHCTRL	on	day	9.	It	is	worth	noting	when	comparing	the	graphs	in	Figure	3.4B	&	
F	 that	both	 the	 control	 and	 knock-down	cells	 had	decreased	proliferative	 rates	 in	 the	2%	
versus	the	10%	FBS	containing	medium.	These	results	suggest	that	the	growth	of	RD	cells	is	
proportional	 to	 the	 levels	of	 growth	 factors	 in	 their	 environment	and	 that	TBX3	does	not	
contribute	 to	 growth	 factor	 independence.	 The	 western	 blots	 in	 Figure	 3.4A,	 B	 &	 F	

















































































































































































































(anchor),	 which	 enables	 them	 to	 form	 tumours.	 To	 assess	whether	 TBX3	 impacts	 on	 this	
characteristic	 of	 RD	 cells,	 soft	 agar	 assays	 were	 performed.	 In	 this	 assay,	 anchorage	
independent	 cells	 will	 proliferate	 and	 form	 colonies	 in	 the	 soft	 agar,	 whereas	 anchorage	
dependent	 cells	 fail	 to	 do	 so.	 Briefly,	 RD	 cells	 were	 suspended	 in	 lower	 percentage	 soft	
agar/media	 slurry	 on	 top	 of	 a	 higher	 percentage	 agar/media	 base,	 and	 after	 30	 days	 the	
plates	 were	 stained	 with	 p-iodinitrotetrazolium	 chloride	 and	 the	 colonies	 visualized	 by	
microscopy.	 Figure	 3.5A	 (top	 panel)	 shows	 microscopic	 images	 of	 stained	 SHCTRL	 and	
SHTBX3	cells	at	day	1	after	plating.	This	was	done	to	confirm	that	a	comparable	number	of	











and	 establish	 colonies	 at	 new	 locations	 (Hanahan	 &	 Weinberg,	 2011).	 To	 investigate	
whether	 TBX3	 impacts	 these	 later	 stages	 of	 tumourigenesis	 the	 migratory	 ability	 of	 the	
SHCTRL	and	SHTBX3	knock-down	cell	lines	were	compared	using	a	two-dimensional	in	vitro	
cell	motility	assay.	Briefly,	 cells	were	grown	to	confluence	and	 then,	using	a	pipette	 tip,	a	
linear	scratch	was	made	through	the	cell	monolayer.	Mitomycin	C,	which	prevents	de	novo	
cell	 proliferation,	 was	 added	 to	 exclude	 effects	 of	 cell	 proliferation	 on	 the	 results.	 Light	
microscopy	images	were	taken	at	three-hour	intervals	from	the	time	the	scratch	was	made	






assays,	 the	 SHTBX3	 (2)	 cells	migrated	 significantly	more	 slowly	 than	 the	 SHTBX3	 (1)	 cells.	
This	again	suggests	that	the	impact	of	TBX3	on	the	cancer	phenotype	is	directly	proportional	
to	the	levels	of	the	protein	because	as	mentioned	earlier,	TBX3	was	consistently	seen	to	be	






While	 results	 from	 the	 above	 in	 vitro	 assays	 suggested	 that	 TBX3	 promotes	











ERMS	was	 therefore	 tested	 in	 an	 in	 vivo	mouse	model	 involving	MF-1	 nude	mice	 (nu/nu	
BALB/c,	 Charles	River	 strain).	 These	mice	were	used	because	 they	have	a	deteriorated	or	
absent	thymus	making	them	immunocompromised	and	hence	useful	for	homo-	and	hetero-
transplants	 (xenografts)	 in	 cancer	 research	 (Pantelouris,	 1968).	 Based	 on	 the	 conditions	
described	in	published	reports	where	the	tumour	forming	ability	of	RD	cells	were	described,	
a	 pilot	 study	was	 conducted	using	3	 x	 106	RD	 cells	 injected	 subcutaneously	 into	 the	 right	






3.2.2	 Establishment	 and	 characterisation	 of	 the	 ERMS	 cell	 culture	
model	in	which	TBX3	was	overexpressed		
	
The	 TBX3	 knock-down	 cell	 culture	 model	 established	 and	 characterised	 in	 this	 study	
suggests	 that	 TBX3	may	 promote	 rhabdomyosarcomagenesis	when	 it	 is	 overexpressed.	 It	
was	 therefore	 hypothesised	 that	 further	 increasing	 the	 levels	 of	 TBX3	 in	 RD	 cells	 would	
result	in	a	more	aggressive	cancer	phenotype.	As	there	is	some	controversy	in	the	literature	
as	 to	whether	 the	 TBX3	 and	 TBX3+2a	 isoforms	 have	 distinct	 or	 redundant	 functions,	 this	
study	also	aimed	to	determine	if	both	isoforms	could	promote	the	oncogenic	phenotype	of	
RD	cells.	 To	 this	end,	Flag-tagged	mouse	 (m)tbx3	and	mtbx3+2a	 isoforms,	 that	 share	98%	
amino	acid	sequence	identity	with	their	human	counterparts	(Bamshad	et	al.,	1997),	were	
stably	 transfected	 in	 the	RD	cells.	Transfectants	were	selected	 for	with	G-418	 (0.8	mg/ml)	
and	 successful	 overexpression	 of	 Flag-mtbx3	 and	 Flag-mtbx3+2a	 protein	 and	 mRNA,	
compared	 to	 the	 control	 cell	 line,	 was	 confirmed	 using	 western	 blotting	 and	 qRT-PCR	
respectively	(Fig.3.7).		
	




The	 next	 experiments	 explored	 the	 impact	 of	 Flag-mtbx3	 and	 Flag-mtbx3+2a	 on	 the	
morphology	and	proliferative	ability	of	RD	cells.	 In	support	of	 the	knock-down	data,	while	
overexpressing	 either	 TBX3	 isoforms	 has	 no	 effect	 on	 RD	 cell	 morphology	 (Fig.3.8A),	







statistically	 significant.	Whether	 this	 is	 a	 dose	 effect,	 because	 the	mtbx3+2a	 isoform	was	







To	 determine	 whether	 Flag-mtbx3	 and	 Flag-mtbx3+2a	 are	 able	 to	 promote	 anchorage-







ability	 of	 RD	 cells	 to	 proliferate	 independent	 of	 a	 substrate	 (Fig.3.9A	 &	 B)	 and	 migrate	
(Fig.3.9C)	 but	 only	 the	 results	 obtained	 for	 the	 Flag-mtbx3+2a	 were	 significant.	 As	
mentioned	earlier,	 this	may	be	as	a	 result	of	a	dosage	sensitivity	 response	since	 the	Flag-
mtbx3+2a	 cell	 line	 consistently	 expressed	 slightly	 higher	 levels	 of	 TBX3,	 as	 shown	 in	 the	
accompanying	western	blots	(Fig.3.9B	&	C).	
	
3.2.2.3	 The	 effect	 of	 Flag-mtbx3+2a	 overexpression	 on	 tumour	
formation	of	RD	cells	in	vivo	
	
The	 above	 results	 suggested	 that,	 statistically,	Flag-mtbx3+2a	 had	 a	 greater	 impact	
on	rhabdomyosarcomagenesis	 and	 therefore	 the	 effect	 of	 overexpressing	 this	 isoform	 on	
RD	 tumour	 forming	 ability	 in	 nude	mice	was	 tested.	 Based	 on	 the	 results	 from	 our	 pilot	
study	described	in	the	knock-down	cell	culture	model	(see	section	3.2.1.5),	1	x	107	(instead	




Flag	 Empty	 tumour	 cells	 (Fig.3.10B).	 These	 results	 suggested	 that,	 consistent	 with	 the	in	
vitro	assays,	 TBX3	promotes	 the	 cancer	 phenotype	of	 RD	 cells.	Quite	 unexpectedly,	when	
the	tumours	were	excised	and	weighed	at	 the	6	week	end	point,	 the	Flag	Empty	tumours	
weighed	 significantly	 more	 than	 the	 Flag-mtbx3+2a	 tumours	 (Fig.3.10C).	 Furthermore,	 it	
was	noted	that	whereas	tumours	 from	mice	 injected	with	the	Flag	Empty	cells	had	a	 long	
and	 flattened	appearance,	 tumours	 from	mice	 injected	with	 the	Flag-mtbx3+2a	cells	were	
more	spherical	or	rod	shaped	in	appearance	(Fig.3.10D).	Tumours	were	then	processed	for	
histopathological	analysis	and	tumour	sections	stained	with	haematoxylin	and	eosin	(H&E)	
and	examined	by	a	pathologist,	 Professor	Dhiren	Govender	 (Fig.3.11).	All	 tumour	 sections	
displayed	 general	 pleomorphic	 morphology,	 with	 cells	 differing	 in	 shape	 and	







































































































































mtbx3+2a	 tumour	 tissue	 sections	 displayed	 predominant	 fascicular	 cell	 growth,	 in	 which	
round	 and	 spindle-shaped	 cells	appear	 to	 grow	 in	 cords	 of	 differing	 polarities	(Fig.3.11E-
H).	In	 brief,	 the	 Flag-mtbx3+2a	 cells	 had	 morphology	 more	 typical	 of	 migratory	 cells.	
Interestingly,	sections	 of	the	 Flag	 Empty	tumours	displayed	 more	 mitotic	 cells	(8-12	
counts	compared	to	2-3	counts	per	high	powered	field	of	view,	data	not	shown).	While	both	
















In# vivo# tumour! forma)on! was! assayed! by! subcutaneously! injec)ng! 1x107! RD! Flag! Empty! and! Flag?
mbx3+2a!cells! into!4?6!week?old!athymic!nude!mice!(N=7!each).!Mice!were!photographed!at!week!4!
once! visible! tumour! forma)on! occurred! (indicated! by! the! black! arrow).! (B)# In# situ# tumour! volume!
(mm3)! was! measured! over! the! 6! week! period! using! callipers,! average! tumour! volume! ploOed! per!
group,!error!bars!represent!standard!devia)on.!(C#&#D)#Mice!were!euthanised!aPer!6!weeks!and!the!















































































previous	PhD	 student	 in	 the	Prince	 laboratory,	Dr	Willmer,	performed	mass	 spectrometry	
and	identified	several	putative	TBX3	co-factors	in	chondrosarcoma.	Of	these	she	went	on	to	
validate	Hsc70	and	nucleolin	 as	bona	 fide	 TBX3	 co-factors	 and	 further	demonstrated	 that	
whereas	Hsc70	plays	a	critical	role	in	stabilizing	the	TBX3	protein,	nucleolin	was	required	for	




Figure% 3.11.% H&E% histopathology% of% RD% Flag% Empty% and% Flag+mtbx3+2a% tumour% Assues.% In# vivo# tumour&
forma)on&was&assayed&by&subcutaneously&injec)ng&1x107&RD&Flag&Empty&and&Flag?mtbx3+2a&cells&into&4?6&
week?old& nude& mice& (N=7& each).& Mice& were& euthanised& aMer& 6& weeks& and& the& tumours& removed& and&
processed&with&haematoxylin&and&eosin&(H&E)&staining&for&histopathological&analysis.&Representa)ve&phase&
contrast& light& microscopic& images& of& the& indicated& cell& lines& photographed& using& a& Canon& camera&
(PowerShot&S50).&Microscopic&images&of&cells&were&taken&at&200X&and&400X&magnifica)on.&(A#D)&Flag&Empty&


















Nucleolin	 is	 a	 ubiquitous,	 highly	 conserved,	 multifunctional	 phosphoprotein	 that	 is	
traditionally	 known	 for	 its	 roles	 in	 ribosome	 biogenesis	 (Srivastava	et	 al.,	 1989;	 Tuteja	 &	
Tuteja,	 1998;	 Ginisty	et	 al.,	 1999).	 While	 it	 is	 most	 abundant	 in	 the	 nucleolus,	 it	 is	 also	




nucleo-cytoplasmic	 transport	 and	 shuttling,	 mRNA	 stability,	 centriole	 and	 microtubule	
organization,	 cytokinesis,	 cell	 adhesion	 and	 cell	 signaling	 (reviewed	 in	 Abdelmohsen	
&	Gorospe,	2012).	Aberrant	expression	of	nucleolin	has	been	associated	with	a	wide	range	
of	 cancers	 including	 breast,	 lung,	 gastric,	 cervical	 and	 colorectal	 cancers,	 chronic	
lymphocytic	 leukaemia,	hepatocellular	carcinoma,	renal	cell	carcinoma,	non-small	cell	 lung	
carcinoma,	melanoma	and	paediatric	intracranial	ependymoma,	and	it	has	been	connected	
with	 cancer	 initiation,	 progression,	 tumour	 aggressiveness,	 drug	 resistance	 and	 poor	




It	 was	 hypothesized	 that,	 similar	 to	 the	 data	 obtained	 in	 chondrosarcomas,	 TBX3	 and	
nucleolin	may	 interact	 and	 co-operate	 to	 promote	 the	 proliferation	 and	migration	 of	 RD	
cells.	To	test	this,	 immunoprecipitation	assays	were	firstly	performed	to	establish	whether	











To	 further	 validate	 the	 TBX3-nucleolin	 interaction,	 RD	 cells	 were	 processed	 for	




to	 visualize	 nuclei	 (blue	 channel)	 and,	 as	 negative	 controls,	 the	 primary	 antibodies	 were	
excluded	and	cells	were	incubated	with	only	secondary	antibodies	used	to	detect	TBX3	and	
nucleolin	(data	not	shown).	The	co-localisation	between	TBX3	and	nucleolin	was	quantified	
using	 Zen	 (Carl	 Zeiss)	 imaging	 software.	 Figure	 3.12D	 shows	 a	 representative	 two-
dimensional	scatter	plot	of	the	staining	 intensities	of	nucleolin	(quadrant	1,	bottom	right),	
TBX3	 (quadrant	2,	 top	 left)	and	 the	overlap	between	 the	TBX3	and	nucleolin	 (quadrant	3,	
top	right).	The	coincidence	of	nucleolin	and	TBX3	co-localising	was	quantified	with	Pearson’s	
(PCC)	 and	 Manders’	 (MCC)	 correlation	 coefficients,	 as	 well	 as	 weighted	 co-localisation	
coefficients	(WCC).	The	PCC	value	defines	the	overall	correlation	between	two	channels	as	a	
value	between	-1	and	1,	where	a	value	of	1	represents	perfect	co-localisation	and	a	value	of	
-1	 represents	 perfect	 exclusion.	MCC	 values	 range	 between	 0	 and	 1,	 where	 a	 value	 of	 1	
represents	 high	 co-localisation	 and	 0	 represents	 low	 co-localisation.	 Importantly,	 these	
values	are	determined	independently	for	each	channel	thereby	measuring	the	proportion	of	
TBX3	 co-localising	 with	 nucleolin	 and	 visa	 versa.	WCC	 values	 range	 from	 0	 to	 1	 where	 a	
value	of	0	 indicates	random	staining	and	a	value	of	1	 indicates	dependent	staining.	Figure	
3.13E	 summarises	 the	 results	 of	 PCC,	MCC	and	WCC	 calculated	 from	20	 random	 fields	 of	
view.	The	MCC	values	report	low	co-localisation	of	total	TBX3	with	nucleolin	(MCC	=	0.04),	
which	 is	 expected	 as	 the	 area	 and	 subcellular	 locations	 of	 TBX3	 expression	 is	 more	




localise	 with	 very	 high	 levels	 of	 nucleolin	 expression.	 Importantly,	 the	 PCC	 value	 is	 0.65	
which	 is	 close	 to	 1	 and	 therefore	 suggests	 co-localisation	 between	 TBX3	 and	 nucleolin	
indicating	 possible	 interaction	 between	 these	 two	 proteins.	 In	 the	 future,	 co-localisation	
should	be	measured	within	the	nucleus	only,	as	opposed	to	the	whole	cell,	as	we	expect	the	
TBX3/nucleolin	 interaction	 to	 occur	 largely	 within	 the	 nucleus,	 and	 this	 may	 therefore	
improve	the	co-localisation	co-efficient	values	for	TBX3.		
	






proliferation	 and	 migration	 respectively.	 Western	 blots	 confirm	 that	 nucleolin	 was	
successfully	knocked	down	in	these	experiments	(Fig.3.13A	&	B).	Consistent	with	the	above	
data,	 results	 from	 experiments	where	 nucleolin	was	 transiently	 overexpressed	 show	 that	
like	TBX3,	nucleolin	also	promotes	RD	cell	proliferation	and	migration	(Fig.	3.13C	&	D).		The	
next	 set	 of	 experiments	 was	 performed	 to	 investigate	 whether	 knocking	 down	 or	
overexpressing	 nucleolin	 could	 influence	 the	 ability	 of	 TBX3	 to	 promote	 proliferation	 or	
migration.	Firstly,	nucleolin	was	transiently	silenced	in	Flag	Empty	and	Flag-mtbx3+2a	cells	
using	siRNA	and	the	effect	on	cell	proliferation	measured	using	a	growth	curve	assay.	Please	
note	 that,	 instead	 of	 the	 Flag-mtbx3	 cells,	 the	 Flag-mtbx3+2a	 cells	 were	 used	 for	 these	
experiments	because	 they	proliferated	and	migrated	significantly	 faster	 than	control	cells.	
Figure	3.14A	confirms	the	overexpression	of	Flag-mtbx3+2a	and	the	efficacy	of	the	siRNA	to	
nucleolin	in	this	experiment.	Consistent	with	previous	observations	in	this	study,	compared	
with	 Flag	 Empty	 +	 siCTRL	 cells,	 Flag-mtbx3+2a	 +	 siCTRL	 cells	 had	 enhanced	 proliferative	
ability	 and	 Flag	 Empty	 +	 siNucleolin	 cells	 proliferated	 significantly	 slower	 (Fig.3.14B).	
Importantly,	 depleting	 nucleolin	 in	 Flag-mtbx3+2a	 overexpressing	 cells	 (Flag-mtbx3+2a	 +	













































monoclonal!Flag!M2!(Sigma)! (1:1000),! rabbit!polyclonal!TBX3!(1:1000),!mouse!polyclonal!nucleolin! (1:1000)!
and! secondary! A/G! protein! (1:5000).! (B)# RD! cells! were! plated! on! coverslips! and! processed! for!
immunofluorescence! with! an8bodies! specific! to! TBX3! (Cy3;! red! channel)! and! nucleolin! (Alexa! 488;! green!
channel)!and!visualised!by!confocal!microscopy.!Representa8ve!images!are!shown!at!400X!magnifica8on.!All!
cells! were! co9stained! with! Hoechst! to! determine! the! loca8on! of! the! nuclei.! (C)#Merged! image! from! co9
localisa8on!analysis!with!white!pixels!indica8ng!TBX3!and!nucleolin!co9localisa8on.!(D)#Representa8ve!scaXer!
plot!of!TBX3!and!nucleolin!co9localisa8on!in!RD!cells.!Images!from!(C)#were!analysed!by!Zeiss!so[ware!where!






































































































































































































construct	 in	 RD	 SHCTRL	 and	 SHTBX3	 cells	 and	 growth	 curve	 assays	 performed.	 Western	
blotting	 confirmed	 the	 overexpression	 of	 nucleolin	 and	 the	 knock-down	of	 TBX3	 in	 these	
experiments	 (Fig.	 3.14C).	 As	 anticipated,	 overexpressing	 nucleolin	 could	 not	 rescue	 the	
effect	of	silencing	TBX3	on	cell	proliferation	(Fig.	3.14D).	If	anything,	in	the	absence	of	TBX3,	
the	 overexpression	 of	 nucleolin	 appeared	 to	 be	 cytotoxic	 and	 killed	 the	 cells	 from	 day	 3	
(data	 not	 shown).	 To	 determine	whether	 TBX3	 and	 nucleolin	 co-operate	 to	 promote	 cell	
migration,	 the	 same	 experimental	 conditions	 as	 described	 above	 were	 used	 and	 scratch	
motility	 assays	 were	 performed.	 Results	 showed	 that	 TBX3	 and	 nucleolin	 both	 positively	
impact	on	cell	migration	and	partly	require	each	other	to	do	this	(Fig.	3.14E	&	F).		
	
3.3.3	 Heat	 shock	 cognate	 70	 (Hsc70)	 binds	 and	 co-localises	 with	
TBX3	in	RD	cells	in	vivo		
	
Hsc70	 belongs	 to	 the	 heat	 shock	 protein	 (Hsp)	 70	 family	 of	molecular	 chaperones	which	
plays	 an	 important	 role	 in	 maintaining	 protein	 homeostasis	 through	 (1)	 protecting	 the	

















































































































































































within	 cells	 and	 organelles,	 (3)	 chaperone-mediated	 autophagy,	 (4)	 preventing	 an	
accumulation	of	proteotoxic	protein	 aggregates	 and	 (5)	uncoating	 clathrin-coated	 vesicles	
(reviewed	in	Mayer	&	Bukau,	2005;	Murphy,	2013;	Lui	et	al.,	2012	and	Liao	&	Tang,	2014).	
Members	of	the	Hsp70	family	have	also	been	implicated	in	oncogenesis	and	of	importance	
to	 this	 study	 are	 observations	 that	 Hsc70	 is	 overexpressed	 in	 several	 cancers	 and	 was	




and	 Flag-mtbx3+2a	 overexpressing	 cells	 and	 anti-Flag	 agarose	 beads.	 Immune	 complexes	
were	 then	 analysed	 by	 western	 blotting	 using	 antibodies	 against	 Flag,	 TBX3	 and	 Hsc70.	
Figure	 3.15A	 shows	 that	 the	 Flag	 agarose	 beads	 did	 indeed	 immunoprecipitate	 the	 Flag-
mtbx3	 and	 Flag-mtbx3+2a	 proteins	 and	 that	 Hsc70	 is	 in	 complex	 with	 both	 these	 TBX3	
isoforms.		
	
In	 light	 of	 the	 above	 results,	 immunocytochemistry	 and	 confocal	 microscopy	 were	
performed	 to	 determine	 if	 TBX3	 (red	 channel)	 and	Hsc70	 (green	 channel)	 co-localise	 and	
therefore	 possibly	 interact	 in	 RD	 cells.	 It	 is	 important	 to	 note	 that	 both	 TBX3	 and	 Hsc70	
expression	 levels	and	nuclear	 localization	peak	 in	S-phase	(Willmer	et	al.,	2015;	Milarski	&	
	 92	
Morimoto,	1987)	and	that	 initial	 findings	 in	asynchronous	cells	 revealed	weak	cytoplasmic	
staining	 for	 Hsc70.	 Therefore	 to	 enrich	 for	 possible	 TBX3:Hsc70	 co-localisation	 and	
interaction,	RD	 cells	were	 subjected	 to	 a	double-thymidine	 S-phase	block	 as	described	by	














et	al.,	2006;	Wan	&	Helman,	2003;	Ridzewski,	2015).	 In	addition,	work	done	 in	 the	Prince	






















































it.% Purified% immune% complexes% were% subjected% to% western% blot% analysis% using% mouse% monoclonal% M2% Flag%
(1:1000),%rabbit%polyclonal%TBX3%(1:1000)%and%mouse%monoclonal%Hsc70%(1:1000).%(B)#RD%cells%were%plated%on%




pixels% indica@ng% TBX3% and% Hsc70% co+localisa@on.% (D)# Representa@ve% scaXer% plot% of% TBX3% and% nucleolin%
colocalisa@on%in%RD%cells.%Images%from%(C)#were%analysed%by%Zeiss%so[ware%where%the%signal%intensity%of%each%







































number	 of	 sarcomas,	 including	 liposarcoma,	 fibrosarcoma,	 synovial	 sarcoma,	
chondrosarcoma,	 osteosarcoma,	 Ewing’s	 sarcoma	 and	 Kaposi’s	 sarcoma	 (Barrios	 et	 al.,	
1994;	Barrios	et	al.,	1993;	Castresana	et	al.,	1992;	Demir	et	al.,	2014;	Sollazzo	et	al.,	1999).	
Importantly,	c-Myc	is	overexpressed	in	the	RD	cell	line	(Kouraklis	et	al.,	1999;	Marampon	et	





also	 be	 upregulated	 by	 c-Myc	 in	 RD	 cells.	 To	 this	 end	 the	 impact	 of	 transiently	 knocking	
down	c-Myc	on	TBX3	levels	in	RD	cells	was	explored	using	a	siRNA	approach.	Western	blot	
analyses	with	antibodies	to	c-Myc	confirmed	the	efficacy	of	the	two	siRNA	to	c-Myc	used	in	
this	 study	 and	 antibodies	 to	 TBX3	 show	 that	 there	 is	 a	 corresponding	 decrease	 in	 TBX3	
protein	 levels	 when	 c-Myc	 is	 depleted	 (Fig.3.16A).	 These	 results	 suggest	 that	 c-Myc	may	
indeed	 act	 upstream	 of	 TBX3	 to	 increase	 its	 expression.	 To	 confirm	 this	 qRT-PCR	 was	






AKT2	 and	 AKT3	which	 are	 activated	 by	 phosphorylation	 (p-AKT).	 AKT	 overexpression	 and	
hyperactivity	have	been	implicated	in	a	number	of	sarcomas	including	RMS	(Wan	&	Helman,	
2003;	 Ridzewski,	 2015).	 Additionally,	 Peres	 et	 al.	 (2015)	 recently	 reported	 that	 AKT3	
upregulates	 TBX3	 protein	 levels	 in	 a	 subset	 of	 melanoma	 cell	 lines	 by	 increasing	 its	
stabilization	through	phosphorylation.	The	possibility	that	AKT	may	also	upregulate	TBX3	in	




al.,	 2005).	 The	 concentration	 and	 duration	 of	 treatment	with	 this	 inhibitor	was	 based	 on	
optimization	experiments.	Western	blot	analyses	with	an	antibody	 to	phosphorylated	AKT	
i.e.	 the	active	form	of	the	kinase	show	that	the	AKT	pathway	 is	constitutively	active	 in	RD	
cells	 and	 that	 the	 pathway	 was	 effectively	 blocked	 at	 2h	 and	 4h	 of	 AKT	 VIII	 treatment	
(Fig.3.16C).	 Importantly,	 as	 seen	 in	Figure	 3.16C,	 TBX3	protein	 levels	were	 reduced	 at	 2h	
and	4h	of	AKT	VIII	treatment	suggesting	that	TBX3	was	indeed	activated	by	the	AKT	pathway	
in	RD	cells.	Furthermore,	our	laboratory	has	unpublished	data	implicating	AKT1	in	regulating	
TBX3	 levels	 in	 fibrosarcomas.	Therefore	to	 identify	which	AKT	 isoform	may	be	responsible	
for	upregulating	TBX3	in	RD	cells,	the	cells	were	transiently	transfected	with	a	siRNA	to	AKT1	













soft	 tissue	 sarcoma	 in	 children	 (Ries	 et	 al.,	 1999).	 Decreased	mortality	 and	 increased	 life	
expectancy	 may	 be	 achieved	 by	 early	 detection,	 accurate	 diagnosis	 and	 more	 effective	
chemotherapeutic	treatments.	There	is	therefore	an	urgent	need	to	elucidate	the	molecular	
mechanisms	 underpinning	 RMS	 formation	 because	 it	will	 reveal	 novel	 diagnostic	markers	
and	 targets	 for	 therapeutics.	 There	 is	 a	 large	 body	 of	 evidence	 implicating	 T-box	
transcription	 factor	 TBX3	 as	 an	 oncogene	 in	 several	 cancers	 of	 epithelial	 origin,	 yet	 until	
recently	little	was	known	about	the	status,	role	and	regulation	of	TBX3	in	sarcomas	(Fan	et	
al.,	2004;	Rowley	et	al.,	2004;	 Ito	et	al.,	2005;	Renard	et	al.,	2007;	Rodriguez	et	al.,	2008).	
Our	 laboratory	has	however	 shown	 that	TBX3	 is	upregulated	 in	 several	 sarcoma	subtypes	
including	human	embryonal	RMS	cells	(ERMS),	and	provided	compelling	data	showing	that	
whereas	 TBX3	 promotes	 oncogenesis	 in	 chondrosarcomas	 it	 functions	 as	 a	 tumour	









resulting	 cells	 subjected	 to	 a	number	of	 assays	 to	determine	 the	 consequence	of	 altering	
TBX3	 levels	 on	 the	 cancer	 phenotype.	 The	 results	 showed	 that	 TBX3	 does	 indeed	 impact	
directly	 on	 the	 ERMS	 phenotype	 because	 when	 it	 is	 knocked	 down	 several	 features	 of	
transformation	 including	 substrate-dependent	 and	 -independent	 proliferation	 and	 cell	
migration	are	inhibited.	 Importantly,	overexpression	of	TBX3	enhanced	RD	cell	proliferation,	
anchorage	independence,	migration	and	tumour	forming	abilities.	Together	the	results	from	
the	 knock-down	 and	 overexpression	models	 generated	 in	 this	 study	 provided	 compelling	
evidence	that	TBX3	was	a	key	driver	of	 the	ERMS	phenotype.	These	results	are	consistent	
	 98	








(Zhu	et	al.,	 2015b).	 Future	 studies	 should	 include	 screening	an	RMS	 tissue	array	 for	 TBX3	








promotes	 cell	 proliferation	 of	 ERMS	 cells.	 This	 is	 consistent	 with	 results	 from	 studies	 in	
other	 cancers	 including	 liver	 cancer,	 bladder	 cancer,	 head	 and	 neck	 squamous	 cell	
carcinoma	and	chondrosarcoma	(Renard,	2007;	Burgucu	et	al.,	2012;	Humtsoe	et	al.,	2012;	
Wilmer	et	al.,	2016).	While	the	current	study	did	not	explore	the	mechanism	by	which	TBX3	
promotes	 RD	 cell	 proliferation	 it	 has	 previously	 been	 shown	 to	 function	 as	 a	 pro-
proliferative	 factor	by	bypassing	senescence	and/or	 inhibiting	apoptosis	 through	 its	ability	
to	repress	p14/p19	and	p21	(Brummelkamp	et	al.,	2002;	Carlson	et	al.,	2002;	Lingbeek	et	al.,	









al.,	 2015b).	 The	 authors	 show	 that	 this	 results	 in	 the	 loss	 of	 terminal	 myogenic	




TBX3	which	will	be	essential	 to	resolve	 in	 the	 future.	Nevertheless,	 it	will	be	 important	 to	
investigate	 whether	 TBX3	 can	 promote	 the	 ERMS	 phenotype	 by	 similarly	 disrupting	
p14/p19,	p21	and	the	myogenic	transcription	factors.	This	will	be	particularly	interesting	in	
light	of	reports	that	TBX3	is	highly	expressed	in	undifferentiated	mouse	skeletal	muscle	cells	
and	 tissues	 and	 that	 the	 overexpression	 of	 TBX3	 prevents	 skeletal	muscle	 differentiation	
(Carlson	et	al.,	2002).	 Furthermore,	Nanni	et	al.	 (2009)	 showed	that	cell	proliferation	and	
migration	 of	 RMS	 cells	 ceased	 upon	 terminal	 muscle	 differentiation.	 Importantly,	 they	




line	 caused	 no	 change	 in	 cell	 morphology	 but	 triggered	 an	 S-phase	 arrest	 and	 increased	
apoptosis.	 This	 is	 consistent	 with	 other	 reports	 that	 TBX3	 may	 also	 promote	 cancer	 cell	
proliferation	 by	 inhibiting	 apoptosis	 (Brummelkamp	 et	 al.,	 2002;	 Carlson	 et	 al.,	 2002).	
Furthermore,	this	effect	has	also	been	seen	in	the	Prince	laboratory	in	chondrosarcoma	cell	
lines	 in	which	TBX3	has	been	knocked	down	(Willmer	et	al.,	2015).	 It	 is	 important	to	note	
however	that	the	SHTBX3	(1)	RD	cell	 line	did	not	exhibit	an	S-phase	arrest	or	apoptosis.	A	
possible	explanation	 for	 this	difference	between	 the	SHTBX3	 (1)	and	SHTBX3	 (2)	 cell	 lines	
could	 be	 the	 degree	 to	 which	 TBX3	 is	 knocked	 down	 in	 these	 two	 cell	 lines	 i.e.	 a	 dose-
dependent	 effect.	 This	 is	 a	 real	 possibility	 because	 T-box	 factors	 are	 known	 to	 display	







Quite	 unexpectedly,	 while	mice	 injected	 with	 Flag-mtbx3+2a	 overexpressing	 cells	 initially	
formed	 tumours	 earlier	 than	mice	 injected	with	 Flag	 Empty	 cells,	 upon	 dissection	 of	 the	
tumours	the	Flag	Empty	tumours	were	larger	and	weighed	significantly	more	than	the	Flag-
mtbx3+2a	 tumours.	To	 gain	 insight	 into	 this	 observation,	 histopathological	 analyses	 were	
performed	with	H&E	 staining.	The	 pathologist’s	 report	 indicates	 that	 Flag	 Empty	 tumours	
have	 a	 greater	 mitotic	count	 which	 indicates	 that	 these	 tumour	 cells	 had	 a	 greater	
proliferative	rate	than	the	Flag-mtbx3+2a	tumour	cells.	To	confirm	this	finding	Ki-67	staining	
of	tumour	sections	could	be	performed	to	quantify	the	proliferative	 indices	of	the	tumour	
cells.	 It	 is	 interesting	 to	 note,	 however,	 that	 the	 Flag-mtbx3+2a	 tumour	 cells	displayed	 a	
more	migratory	morphology	and	appeared	to	be	more	invasive	that	the	Flag	Empty	tumour	
cells.	 It	 is	 therefore	 tempting	 to	 speculate	 that	 while	 not	 seen	 in	 vitro,	 in	 vivo,	 the	
proliferation/migration	dichotomy	may	apply	with	TBX3	overexpressing	cells	 favouring	cell	
migration/invasion	 over	 proliferation.	 It	must	 also	 be	 mentioned	 that	 in	 carcinoma	 cells	
undergoing	 epithelial-to-mesenchymal	 transition	 (EMT)	 cell	morphology	 often	 changes	 to	
become	more	spindle-shaped	allowing	the	cell	to	become	more	migratory	and	invasive.	To	
further	 investigate	 this	 possibility	it	would	 be	 essential	 to	 perform	immunohistochemistry	
on	 the	 tumour	 sections	with	antibodies	 to	EMT	markers	as	well	as	to	carry	out	 trans-well	
invasion	assays	with	Flag	Empty	and	Flag-mtbx3+2a	cells.	
	
This	 study	 did	 not	 explore	 the	 mechanism(s)	 by	 which	 TBX3	 may	 promote	 anchorage	
independent	growth,	migration,	 in	vivo	tumour	forming	ability	and	invasion	of	RD	cells.	To	
address	 this,	 future	 experiments	 will	 need	 to	 perform	 chromatin	 immunoprecipitation	





The	 molecular	 mechanisms	 that	 regulate	 the	 diverse	 roles	 of	 TBX3	 in	 development	 and	
cancer	are	still	 largely	unknown	but	there	 is	a	widely	held	view	that	 it	will	 involve	protein	
co-factors.	To	date,	very	few	TBX3	co-factors	have	however	been	identified.	A	previous	PhD	
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student	 in	 the	 Prince	 laboratory,	 Dr	 Willmer,	 therefore	 performed	 affinity	 purifications	
coupled	 with	 mass	 spectrometry	 analyses	 (AP-MS)	 to	 identify	 TBX3	 interaction	 protein	
partners	that	may	mediate	its	oncogenic	roles	in	chondrosarcomas.	From	the	37	candidate	
proteins	 identified	 nucleolin	 and	 Hsc70	 were	 further	 validated	 as	 co-factors	 of	 TBX3.	
Importantly,	nucleolin	was	shown	to	co-operate	with	TBX3	to	promote	chondrosarcoma	cell	
proliferation	 and	migration	 and	 Hsc70	 stabilised	 the	 TBX3	 protein	 leading	 to,	 in	 part,	 its	
upregulation	in	chondrosarcomas	(unpublished	data).	This	study	was	therefore	interested	to	
determine	 if	 nucleolin	 and	 Hsc70	 also	 interacted	 with	 TBX3	 in	 ERMS	 and	 indeed,	 using	
immunoprecipitation	assays	and	co-localisation	experiments	shows	this	to	be	the	case.		
Based	 on	 the	 data	 obtained	 in	 chondrosarcomas	 it	 was	 hypothesized	 that	 nucleolin	 co-
operated	with	TBX3	to	promote	cell	proliferation	and	migration	in	RD	cells.	There	is	overlap	
between	the	 roles,	upstream	activators	and	some	targets	of	TBX3	and	nucleolin	and	both	
are	 involved	 in	 cancer	 pathogenesis.	 For	 example,	 similar	 to	 TBX3,	 the	 levels	 of	 nucleolin	
peak	 in	 S-phase	 and	 it	 is	 well	 characterized	 for	 its	 roles	 in	 stimulating	 proliferation,	




like	 TBX3,	 nucleolin	 also	 promotes	 RD	 cell	 proliferation	 and	 migration.	 Importantly,	
reciprocal	rescue	growth	curves	and	migration	assays	revealed	that	TBX3	and	nucleolin	also	
co-operate	to	promote	both	cell	proliferation	and	migration	of	RD	cells.	It	will	be	important	
for	 future	 studies	 to	 further	 characterize	 the	domains	of	 the	TBX3	and	nucleolin	proteins	
required	 for	 their	 interaction	 because	 it	 could	 reveal	 additional	 ways	 of	 interrupting	 the	
oncogenic	 functions	 of	 TBX3	 and	 nucleolin.	 This	 can	 be	 done	 using	 GST-pull-down	
experiments.	For	the	same	reason	 it	will	be	useful	 to	 identify	TBX3/nucleolin	 target	genes	
that	mediate	their	pro-proliferative	and	pro-migratory	roles	in	RD	cells.	Of	interest	to	their	
pro-proliferative	 role	would	 be	p21	because	 it	 has	 already	been	 identified	 as	 a	 TBX3	 and	
nucleolin	 target	 (Carlson	 et	 al.,	 2002;	 Rodriguez	 et	 al.,	 2008;	 Wilmer	 et	 al.,	 2015).	 This	
possibility	could	be	examined	through	the	following	experiments:	(1)	western	blotting	and	
qRT-PCR	to	determine	the	 impact	of	TBX3	and	nucleolin	on	de	novo	p21	transcription,	 (2)	




to	 regulate	 p21	 gene	 expression	 at	 a	 post-transcriptional	 level,	 as	 both	 have	 been	
implicated	in	RNA	binding	and	are	key	components	of	the	spliceosome	(Ginisty	et	al.,	1998;	
Kumar	et	al.,	2014b).	
It	 was	 speculated	 that	 the	 interaction	 between	 TBX3	 and	 Hsc70	 was	 to	maintain	 TBX3’s	
stability	 and	 therefore	 contributing	 to	 TBX3’s	 oncogenic	 function	 through	 prolonging	 its	
active	period.	 This	would	be	 consistent	with	 a	 reported	 function	of	Hsc70	 in	oncogenesis	
being	through	its	ability	to	bind	and	stabilize	oncoproteins	(Finlay	et	al.,	1989;	Shiota	et	al.,	
2009;	 Koren	 et	 al.,	 2009;	 Ding	 et	 al.,	 2012;	 Tanaka	 et	 al.,	 2014;	 Prince	 laboratory,	
unpublished	 data).	 Furthermore,	 bioinformatics	 analysis	 reveals	 that	 the	 TBX3	 protein	 is	
highly	 disordered	 and	 unstable	 (PSIPRED)	 which	 suggests	 that	 TBX3	 may	 require	 a	
chaperone	protein	to	fold	it	correctly	and	optimally	in	cancers	in	which	it	is	overexpressed.	
To	test	this	western	blot	analysis	of	RD	cells	transfected	with	a	siRNA	to	Hsc70	could	first	be	
performed	 to	 investigate	 if	 a	decrease	 in	TBX3	protein	 levels	 correspond	 to	a	decrease	 in	
Hsc70.	 Confirmation	would	 require	 experiments	with	 the	proteasome	 inhibitor	MG132	 to	
determine	if	TBX3	protein	levels	can	be	rescued	after	Hsc70	knock-down.		
Identification	of	TBX3	upstream	regulators	in	ERMS	
Wilmer	 et	 al.	 (2016)	 found	 TBX3	 to	 be	 overexpressed	 in	 a	 range	 of	 sarcoma	 cell	 lines,	
including	 the	 RDs,	 at	 both	 the	 protein	 and	mRNA	 levels.	 This	 suggests	 that	 TBX3	may	 be	
transcriptionally	and/or	post-transcriptionally	upregulated	in	RD	cells.	This	study	performed	
preliminary	experiments	which	identified	the	oncogenic	transcription	factor,	c-Myc,	and	the	
pro-survival	 kinase,	 AKT,	 to	 be	 upstream	 of	 TBX3	 expression	 in	 the	 RD	 cell	 line.	 Indeed,	
preliminary	 qRT-PCR	 and	 western	 blotting	 data	 show	 that	 when	 c-Myc	 was	 effectively	
knocked	down	by	two	different	siRNAs	there	was	a	corresponding	decrease	in	TBX3	mRNA	
and	protein	 levels.	While	 this	 data	do	not	 conclusively	 show	 that	 c-Myc	directly	 activates	









also	phosphorylate	TBX3	 in	ERMS.	Using	a	 chemical	 inhibitor	of	AKT1,	2	and	3,	 this	 study	









A	 disappointing	 result	 in	 this	 study	 was	 the	 failure	 to	 determine	 the	 impact	 of	 knocking	
down	TBX3	on	 the	 tumour	 forming	ability	of	RD	cells	 in	 immunocompromised	nude	mice.	
Indeed	a	pilot	study,	using	published	conditions,	showed	that	parental	RD	cells	were	unable	
to	 form	tumours	 in	 these	mice	and	therefore	 the	experiment	with	TBX3	knock-down	cells	
could	not	proceed.	After	the	overexpression	cell	culture	was	established	it	was	speculated	
that	 compared	with	 the	 Empty	 control	 cells,	 the	 TBX3-overexpressing	 RD	 cells	may	 have	
enhanced	 tumour	 forming	 ability.	 To	 improve	 the	 likelihood	 of	 this	 occurring	mice	 were	
injected	with	 1	 x	 107	 cells	 compared	 to	 3	 x	 106	 cells	which	were	 used	 in	 the	 pilot	 study.	
Interestingly,	 mice	 injected	 with	 both	 Empty	 control	 cells	 and	 TBX3-overexpressing	 cells	
formed	tumours.	Since,	 technically,	 the	Empty	control	 cells	 should	have	 the	same	tumour	
forming	ability	as	the	parental	cells	 it	will	be	 important	to	repeat	the	pilot	study	using	1	x	




are	 deficient	 in	 B	 cells	 and	 natural	 killer	 cells	 and	 therefore	 more	 immunocompromised	
(Rongvaux	 et	 al.,	 2013;	 Shultz	 et	 al.,	 2005).	 These	 features	 translate	 into	 an	 improved	
tolerance	 of	 the	 engraftment	 of	 human	 cells	 (Iorns	 et	 al.,	 2012;	 Shultz	 et	 al.,	 2005)	




is	 proposed	 for	 the	 role	 and	 regulation	 of	 TBX3	 in	 ERMS	 where	 it	 is	 overexpressed	 (see	
Fig.4).	Briefly,	c-Myc	and	AKT1	were	found	to	be	upstream	of	TBX3	and	both	nucleolin	and	








role	 and	 regulation	 of	 TBX3	 in	 a	 diverse	 range	 of	 sarcoma	 cell	 lines	 and	 tissue	 samples	
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Chapter	6.	Appendix	
Recipes,	reagents	and	figures	
6.1	Plasmids	and	DNA	constructs	
6.1.1	3XFlag-CMV	(Addgene):	
6.1.2	pSuper.neo/GFP	(Oligoengine):	
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6.1.3	pEGFP-Nucleolin	(Addgene):	
	
	
	
6.2	Cell	culture		
	
Mycoplasma	test	mounting	fluid:		
20	mM	Citric	acid 	
55	mM	Na2HPO4.2H2O		
50%	Glycerol 	
pH	to	5.5	and	store	at	4°C		
	
6.3	Protein	isolation	and	western	blotting		
	
Phosphate	buffered	saline	(PBS)/0.1%	Tween		
10X	PBS: 	
80g	NaCl 	
26.8g	Na2HPO4.12H20 	
2g	KCI 	
2.4g	KH2PO4 	
Make	up	to	1L,	pH	to	6.9	and	autoclave 	
For	use	dilute	to	1	X	(100ml	10X	PBS;	make	up	to	1L	with	dH20)		
	
PBS/0.1%	Tween:		
For	membrane	washes,	add	0.1%	Tween	to	1X	PBS		
	
2	X	Protein	loading	dye:	
125	mM	Tris-HCl,	pH	6.5		
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0.4%	SDS 	
10%	β-mercaptoethanol		
20%	glycerol		
	
5	X	Protein	loading	dye:		
10%	glycerol 	
1%	SDS 	
0.25M	Tris-Cl,	pH	6.8		
3mg	Bromophenol	blue	
		
2	X	Boiling	Blue:	10ml		
1M	Tris-HCL,	pH	6.8 	
4ml	10%	SDS 	
1ml	β-mercaptoethanol		
2ml	glycerol 	
1.75ml	dH2O 	
Pinch	of	bromophenol	blue		
Store	at	-20°C		
	
Sodium	Dodecyl	Sulphate	(SDS)-polyacrylamide	gels		
Acryl-bisacryl-amide	mix	(30:08)	
29	g	acrylamide 	
1g	N,N`-methylenebisacrylamide 	
Make	up	to	100	ml,	heat	at	37°C	to	dissolve	chemicals.		
Store	at	4°C,	protected	from	light		
	
10%	Sodium	docecyl	sulphate	(SDS)		
100g	SDS 	
Make	up	to	1L	with	dH20,	pH	to	7.2	
Store	at	RT		
	
10%	Ammonium	persulphate	(APS)		
0.1g	ammonium	persulphate		
Make	solution	up	to	1ml	with	dH20		
Store	at	4°C		
	
Resolving	gel:		
Acryl-bisacryl-amide	mix	(30:08)	(percentage	depending	on	size	of	protein	of	interest)	0.375	
M	Tris	(pH	8.8) 	
0.1%	SDS 	
0.01%	TEMED		
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0.1%	Ammonium	persulphate		
Stacking	gel:		
5%	Acryl-bisacryl-amide	mix	(30:08)	
0.192	M	Tris	(pH6.8) 	
0.1%	SDS 	
0.01%	TEMED		
0.1%	Ammonium	persulphate		
10X	Running	buffer:		
10g	SDS 	
30g	Tris 	
144g	Glycine pH	to	8.3	and	make	solution	up	to	1L	with	dH20 	
For	use	dilute	to	1	X	(100ml	10X	PBS;	make	up	to	1L	with	dH20)	
10X	Transfer	buffer:		
38g	Tris 	
144g	Glycine 	
Make	solution	up	to	1L	with	dH20	and	store	at	4°C 	
For	use	dilute	1	X	(100ml	10	X	Transfer	Buffer,	200ml	Isopropanol	and	700ml	dH20)	
Store	at	4°C		
5%	PBS/T	milk	
5%	powder	milk	(w/v)
Make	up	to	100ml	with	1	XPBS/0.1%	Tween-20	
Store	at	4°C		
Figure	6.1:	PageRuler	Pre-stained	Protein	Marker	
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6.4.	Affinity	purification	assays	
FLAG-lysis	buffer		
50	mM	Tris	HCl,	pH	7.4		
150	mM	NaCl		
1	mM	EDTA		
1%	TRITON	X-100 	
Protease	inhibitors	were	added	before	use: 	
2	μg/ml	aprotinin	
0.7	μg/ml	pepstatin	A	
2	mM	NaF		
0.2	mM	phenylmethanesulphonyl	fluoride	(PMSF)	
Co-immunoprecipitation	assays		
RIPA-IP	buffer		
0.05	M	Tris-HCl,	pH	8		
0.15	M	NaCl		
0.1%	NP-40 	
0.1%	sodium	deoxycholate		
0.1%	SDS 	
5	mM	EDTA 	
1	mM	DTT		
Protease	inhibitors	were	added	before	use:	
1μg/ml	aprotinin	
1μg/ml	pepstatin	
10	mM	NaF		
0.5mM	PMSF		
0.01	mM	sodium	orthovanadate	
2	complete	proteinase	inhibitor	tablets	
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